




ADHD Medication on Child Welfare
Leah Kitashima
Clemson University, lkitash@clemson.edu
Follow this and additional works at: https://tigerprints.clemson.edu/all_dissertations
This Dissertation is brought to you for free and open access by the Dissertations at TigerPrints. It has been accepted for inclusion in All Dissertations by
an authorized administrator of TigerPrints. For more information, please contact kokeefe@clemson.edu.
Recommended Citation
Kitashima, Leah, "ADHD Medication on Child Welfare" (2017). All Dissertations. 1916.
https://tigerprints.clemson.edu/all_dissertations/1916
ADHD Medication on Child Welfare
A Dissertation
Presented to
the Graduate School of
Clemson University
In Partial Fulfillment







Dr. Patrick Warren, Committee Chair
Dr. Scott Baier
Dr. F. Andrew Hanssen
Dr. Curtis Simon
Abstract
This dissertation examines the causal effects of ADHD medication on child welfare,
and investigates the effects of a supplemental income program on the diagnoses of learning
disabilities.
In 2011, 6.4 million children were diagnosed with Attention-Deficit/Hyperactivity
Disorder (ADHD) with nearly 70% of them taking ADHD medication. However, little
causal evidence exists on the effectiveness of ADHD medication. The first two chapters of
this dissertation utilize an instrumental variable strategy to identify the effects of ADHD
pharmaceutical treatment on South Carolina Medicaid children’s academic, behavioral, and
health outcomes. The first chapter estimates the causal effects of ADHD medication on
South Carolina Medicaid students’ elementary, middle, and high school test scores as well
as grade retention. We find mostly adverse effects. If treated with ADHD medication, male
and female students are more likely to repeat a grade and females are less likely to pass
middle and high school state standardized tests. This negative effect is most apparent for
females diagnosed with combined inattentive and hyperactive/impulsive ADHD. In contrast,
ADHD medication improves test performance for males diagnosed with inattentive ADHD
in elementary school, but these effects vanish by middle school.
The second chapter investigates the effects of ADHD medication on the probability
of risky sexual behavior outcomes (STDs and pregnancy), substance abuse disorders, and
injuries. Our findings suggest that pharmacological treatment has substantial benefits on
behavioral outcomes. It reduces the probability of contracting an STD by 3.6 percentage
points (5.8 percentage points if we include STD screening), reduces the probability of having
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a substance abuse disorder by 7.3 percentage points, reduces the probability of injuries by
2.3 percentage points per year, and associated with them Medicaid costs decrease by $88.4,
or 0.054 of a standard deviation.
The final chapter estimates the impact of an infant’s receipt of Social Security
Supplemental Security Income (SSI) disability benefits on future educational achievement
and learning disability diagnoses. We exploit program eligibility discontinuities in birth
weight to obtain plausibly causal estimates of the long-run impacts of disability benefits on
childhood educational achievement. Our findings suggest that individuals who are eligible
for SSI disability benefits are less likely to repeat a grade in elementary and middle school,
but are more likely to have a reported learning disability.
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Chapter 1
ADHD Medication Effects on Primary and
Secondary Students’ Academic Achievement (with
Anna Chorniy)
1.1 Introduction
Attention-deficit/hyperactivity disorder (ADHD) is one of the most common and
fastest growing mental health disorders. By 2012, approximately 11% of children age 4-
17 years old were diagnosed with Attention-Deficit/Hyperactivity Disorder (Visser et al.
(2014)). Children diagnosed with ADHD are more likely to repeat a grade, be enrolled in
special education, and have lower reading and mathematics test scores (Currie and Sta-
bile (2006)). ADHD symptoms of inattentiveness, hyperactivity and impulsivity in the
classroom are believed to contribute to this poor performance (Barkley (2006)).
Of the children diagnosed with ADHD, 69% of them take ADHD prescription medi-
cations for treatment (Visser et al. (2014)). ADHD medication has been shown to mitigate
ADHD symptoms of inattentiveness, hyperactivity and impulsivity (MTA (1999); Swanson
et al. (1993)), leading medical experts to believe that medication could improve academic
productivity (Barkley (2006)). Yet, ADHD medication is controversial due to the trade-off
between easing ADHD symptoms and encountering severe side effects, as well as a lack of
1
evidence on the long-term effects of ADHD medication on a young brain and body. Many
children suffer from side effects such as decreased appetite, weight loss, irritability/anger,
insomnia, headache, stomachache, and dizziness (Barkley (2006); Cascade et al. (2010)).
Despite the large number of children taking medication for ADHD, little evidence
exists on the effects of ADHD medication treatment on academic performance. We utilize
a unique data set that allows us to investigate the causal effect of ADHD treatment on
academic outcomes in both the short-run, in the form of elementary test scores, middle
school test scores and grade retention, and long-run in the form of high school test scores.
To address the endogeneity of ADHD treatment receipt, we use physician prescribing be-
havior as an instrument following Duggan (2005), Dalsgaard et al. (2014), and Chorniy and
Kitashima (2015).Previous research indicates that ADHD is manifested differently across
gender, and that these distinctions become more prevalent in teen years due to hormonal
influences (Hinshaw et al. (2012)). Therefore, we first examine the effects of ADHD med-
ication treatment by gender. Medicaid data allow us to identify the individual’s ADHD
subtype based on symptoms: predominantly inattentive versus combined inattentive and
hyperactive/impulsive symptoms. To our knowledge, our study is the first to consider
heterogenous treatment effects by gender and ADHD subtype: 1) females with combined
inattentive and hyperactive/impulsive ADHD, 2) females with predominantly inattentive
ADHD, 3) males with combined inattentive and hyperactive/impulsive ADHD, and 4) males
with predominantly inattentive ADHD (see further discussion in Section 1.2.1).
Our results suggest that ADHD medications have mostly adverse effects. ADHD
medication increases the probability of grade repetition for both male and female students
and lowers female students’ middle school and high school test performance. The negative
effect of medication on test performance is particularly driven by the subsample of females
diagnosed with combined inattentive and hyperactive/impulsive ADHD and consistent with
human capital accumulation theory, the magnitude of the negative effect increases with
each subsequent grade. We also find evidence that ADHD medication has positive effects
for elementary school males diagnosed with predominantly inattentive ADHD, but these
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effects vanish by middle school.
1.2 Background and previous research
1.2.1 ADHD Symptoms and Gender Distinctions
The National Institute of Mental Health defines attention-deficit/hyperactivity dis-
order (ADHD) as a brain disorder in which individuals display an ongoing pattern of inat-
tention, hyperactivity, and/or impulsivity that interferes with functioning and development.
Inattentive symptoms include difficulty sustaining attention, difficulty in organizing tasks
and activities, and overlooking details resulting in careless mistakes in schoolwork. Children
with hyperactive/impulsive symptoms appear to be constantly in motion or act as if they
are ”driven by a motor”, squirm in their seats, and run around or climb in inappropriate
situations. natbib Males are more likely to be diagnosed with ADHD due to more apparent
symptoms (Akinbami et al. (2011)). Relative to males diagnosed with ADHD, females diag-
nosed with ADHD have lower ratings on hyperactivity, inattention, and impulsivity. On the
other hand, females with ADHD had greater intellectual impairments and more internaliz-
ing problems than males with ADHD (Gershon and Gershon (2002)). Psychologists stress
the importance of considering ADHD gender differences due to females’ hormonal influences
that can greatly affect their behavior. These gender distinctions become more important
as individuals diagnosed with ADHD develop into their teen years. According to Hinshaw
et al. (2012), after females start puberty (between ages nine and 11) and after menstruation
begins (between ages 11 and 14), their hormones can have profound effects. Females with
ADHD in their early teens have more academic problems, more aggressive behavior, and
higher rates of depression than females who do not have ADHD. This pattern contrasts
with many males, whose overt hyperactivity decreases so significantly after puberty that,
for decades, it was thought they outgrew their ADHD (Littman (2012)).
Attention-Deficit/Hyperactivity Disorder is divided into three subtypes based on
the displayed symptoms: predominantly inattentive (henceforth PI-ADHD), predominantly
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hyperactive/impulsive (henceforth PH-ADHD), and combined inattentive and hyperactive/
impulsive (henceforth combined-ADHD), with combined-ADHD being the most prevalent
diagnosis (American Psychiatric Association (1994)). The division of ADHD subtypes is
important to consider given that differing symptoms may be hindering academic perfor-
mance through different mechanisms. Children diagnosed with PI-ADHD may perform
worse in school due to difficulty staying focused on a task or activity. Children diagnosed
with combined-ADHD may perform worse in school because they are unable to control their
impulses and hyperactivity causing them to lose focus.
Due to known gender differences of ADHD, our analysis considers treatment effects
by gender. As a contribution to the literature, we also consider heterogenous treatment
effects based on the individual’s subtype of ADHD. We stratify the sample by gender and
ADHD type: 1) females with combined-ADHD, 2) females with PI-ADHD, 3) males with
combined-ADHD, and 4) males with PI-ADHD.1
1.2.2 ADHD and Education
Attention-deficit/hyperactivity disorder is associated with lower reading and math
standardized test scores, increased grade retention, and an increased probability of being
placed in special education (Loe and Feldman (2007); Currie and Stabile (2006)). Figure
1.1 shows the passing rates for South Carolina students’ 3rd through 8th grade standardized
tests in English and mathematics. Passing rates are shown for the state of South Carolina,
our Medicaid sample that is not diagnosed with ADHD, and our Medicaid sample diagnosed
with ADHD. Consistent with these prior studies, South Carolina Medicaid data show that
individuals diagnosed with ADHD are less likely to meet the state requirements relative to
South Carolina Medicaid individuals not diagnosed with ADHD. Not surprisingly, relative
to the state of South Carolina, the Medicaid sample has lower passing rates.2
Lower academic achievement for children diagnosed with ADHD can have long-run
12.37% of the sample is diagnosed with predominantly hyperactive-impulsive ADHD. Due to the small
number of observations, we are unable to include this subgroup separately.
2Note: these are raw averages. Thus, we are not accounting income and parental educational differences
in these calculations.
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Figure 1.1: South Carolina Academic Performance
Notes: 3rd through 8th grade South Carolina Palmetto Assessment of State Standards (SCPASS) English and
Math passing rates are presented. The passing rates are averaged across the years 2009-2013. State of SC
represents the passing rates of all students in South Carolina (source: http://ed.sc.gov/data/test-scores/state-
assessments/scpalmetto-assessment-of-state-standards-pass/). SC Medicaid Non-ADHD represents our sample of
Medicaid children who have never been diagnosed with ADHD. SC Medicaid ADHD represents our sample of
Medicaid children diagnosed with ADHD.
implications and has been shown to translate into worse labor market outcomes. Fletcher
(2014) finds that individuals diagnosed with ADHD are 10 percentage points less likely to
participate in the labor market. Further, individuals diagnosed with ADHD experience an
earning reduction of approximately 30% and are 15 percentage points more likely to receive
social assistance.3
Although the mechanism of why children diagnosed with ADHD experience lower
academic performance is not fully understood, ADHD symptoms of inattentiveness, hyper-
activity and impulsivity in the classroom are believed to be a contributing factor (Barkley
(2006)). If ADHD medication has the potential to improve academic performance through
mitigation of symptoms, it can be viewed as a type of investment in human capital. Costs
associated with ADHD medication are both pecuniary and non-pecuniary, due to the sus-
ceptibility of side effects such as loss of appetite, weight loss, irritability/anger, insomnia,
headache, stomachache, and dizziness (Barkley (2006); Cascade et al. (2010)). On the other
hand, these side effects can have detrimental effects on academic performance.
3The results are robust when including controls for comorbid health conditions, years of schooling, and
family background. Earnings are conditional on non-zero earnings.
5
1.2.3 The Effects of ADHD Medication
There is a consensus that ADHD medication treatment is effective in mitigating the
core symptoms of ADHD (Swanson et al. (1993), Barkley (2006), MTA (1999)), yet results
on the effects of ADHD medication treatment on academic performance are inconclusive.
Swanson et al. (1993) reviews 336 studies regarding the effects of ADHD medication on
children diagnosed with ADHD. The review showed a consensus that medication treat-
ment produces immediate symptomatic improvement of inattentiveness and hyperactivity.
Importantly, the review agreed that the documented effects of medication on academic
achievement and long-term effects are negligible.
ADHD medication studies that use measures of teacher opinion conclude that ADHD
medication improves academic achievement of children. Barkley and Cunningham (1978)
further explore these studies and find that when these studies use more objective measures
of academic performance, there is little evidence of positive short-term or long-term effects.
Instead, the major effect of ADHD medication appears to be an improvement in classroom
manageability rather than the individual’s own academic performance.
The Multimodal Treatment Study of Children with ADHD (MTA) is one of the
first studies to investigate the short-term effects of ADHD treatment strategies in a clinical
setting. The study randomly assigned 14 months of medication, behavioral therapy treat-
ment, medication and behavioral treatment combined, or community care to 579 children
between the ages of 7 and 9.9 years old. Children assigned to community care could receive
treatments from community providers and, although it was used as the control group, 67.4%
received medication treatment. The study concludes that the combination of medication
and behavior therapy was most effective in reducing hyperactive and inattentive symptoms
but finds no significant differences for academic achievement. A follow-up study conducted
by Molina et al. (2009) investigates the effects of treatment and behavioral therapy eight
years following the initial assignment of treatment. The researchers find that the groups do
not differ significantly in behavioral or academic outcomes.
Currie et al. (2014) make use of a policy change that expanded insurance coverage for
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prescription medications in the province of Quebec, Canada. First they find that the policy
increased the use of ADHD medications by 2.5 percentage points in Quebec in comparison
to the rest of Canada. They find that the policy change is associated with worse outcomes in
the short and longer-run. In particular, after the policy change girls experienced reductions
in their math scores, were less likely to have a post-secondary education, and experienced
a deterioration in parental relationships. For boys, the policy change was associated with
an increase in grade repetition but the authors note that this result could be driven by the
fact that Quebec was increasing their use of grade repetition for boys.
Dalsgaard et al. (2014) use Danish registry data and hospital level variation in
propensities to prescribe pharmacological treatment to measure the causal effects of ADHD
medication treatment on children’s health and criminal outcomes. In a prior version of their
paper, they investigated school outcomes. They note that only 40% of their sample takes
the exit exam compared to the population mean of 95%. They find that ADHD medication
harms children’s academic performance measured by a decrease in the likelihood of taking
the exit exam. Conditional on taking the exit exam, they find no statistically significant
difference between the treated and untreated children.
This paper contributes to the literature by identifying the causal effects of ADHD
medication treatment on short and longer-run educational outcomes for children and adoles-
cents. To our knowledge, our paper is the first to consider heterogeneous treatment effects
based on ADHD subtypes: combined inattentive and hyperactive/impulsive ADHD versus
predominately inattentive ADHD. An advantage of our sample is that in South Carolina
all students, including students with disabilities, are required to participate in standardized
tests. We instrument for ADHD medication treatment with physician propensity to pre-
scribe to address the endogeneity of ADHD medication treatment following Duggan (2005),
Dalsgaard et al. (2014), and Chorniy and Kitashima (2015).
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1.3 Data and Descriptive Statistics
We merge South Carolina Medicaid claims with data on student academic perfor-
mance over the years 2003 to 2013. The dataset includes individuals diagnosed with ADHD
between the ages of 3-18.
The Medicaid claims data include basic demographic information collected to de-
termine Medicaid eligibility and a complete set of health services utilization records for
all individuals: hospital, outpatient, and pharmacy claims. It is supplemented by several
variables from the enrollees’ birth certificates including mother’s age, race, and education.
Following earlier research work that used Medicaid or other administrative claims data (e.g.
Frank et al. (2004)), we compile a set of ICD-9 diagnosis codes to identify individuals di-
agnosed with ADHD.4 Pharmacy claims are used to track all prescription medications that
were filled by a patient and to construct our instrumental variable (see Section 2.4).
The Department of Education data include measures of student performance: el-
ementary and middle school test scores (South Carolina Palmetto Assessment of State
Standards), high school exit exams (High School Assessment Program), and grade repe-
tition.5 The dataset includes information on learning disabilities, whether the individual
qualifies for the free or reduced price lunch program, and whether the individual is English
proficient.6 School specific information include de-identified school IDs, school type, the
district of the school, as well as school quality measures including student-to-teacher ratios,
fraction of teachers with an advanced degree, and spending per student.
Of the original 145,264 individuals who had at least one ADHD-related claim be-
tween 3 and 18 years old, we extract all individuals for whom we were able to identify
4The International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes
are used by Medicaid for reporting purposes.
5South Carolina Palmetto Assessment State Standards includes testing in subjects of English, math,
science, social studies, and writing.
6If a student has a registered learning disability through the school, they may qualify for special education
services. For robustness, we exclude individuals with registered learning disabilities. Results reported in
Section 2.7.
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their first ADHD diagnosis.7,8 Next we eliminate individuals with missing demographic in-
formation and individuals for whom we are unable to construct the instrument, provider
propensity to prescribe. Because we define treatment as treated within a year of the individ-
ual’s ADHD diagnosis, we condition on individuals being consistently eligible for Medicaid
for at least one year.9 Our final Medicaid sample diagnosed with ADHD includes 58,685
ADHD individuals.
For our analysis, we first investigate ADHD medication treatment effects by gen-
der. Consistent with national statistics (Visser et al. (2014)) males make up 66% of the
sample. We further consider heterogenous ADHD medication treatment effects based on
gender and ADHD subtype classification based on symptoms: combined inattentive and
hyperactive/impulsive ADHD (combined-ADHD) versus predominantly inattentive ADHD
(PI-ADHD). Approximately 74% of the sample has combined-ADHD while 24% has PI-
ADHD.10
Table 3.2 reports summary statistics on individual, mother, and family composition
characteristics. Column (1) reports summary statistics by gender. Columns (2) and (3)
report summary statistics based on ADHD subtype classification and by gender. Relative
to the combined-ADHD sample, white females and males make up a larger proportion of
the PI-ADHD sample. On average females are diagnosed at an older age than males. Both
males and females diagnosed with PI-ADHD are diagnosed at a relatively older age than
individuals diagnosed with combined-ADHD. Prior to the individuals’ ADHD diagnoses, we
observe that both females and males with combined-ADHD are more likely to be diagnosed
7Based on Crawford and Shum (2005), we exclude patients who have an ADHD-related claim within
180 days from their first appearance in the sample and patients who fill a prescription prior to their first
observed ADHD-related provider visit. This requirement is necessary to construct the instrumental variable
which uses individual’s diagnosing physician propensity to prescribe. See Section 2.4.
8The original sample makes up approximately 20% of the children in the state.
9On average, we observe every Medicaid enrollee for eight years. Nearly 48% of the enrollees have at
least one lapse in eligibility that exceeds two months, with the median lapse in coverage of eight months.
For lapses in eligibility that last under three months, we assume that patients are enrolled but receive no
medical treatment. For inconsistent eligibility periods that result in longer lapses in coverage, we only keep
medical history prior to the lapse.
102% of the sample has predominantly hyperactive ADHD. For our main analysis we exclude these
individuals. For robustness, we group them into the combined hyperactive/inattentive group. Results
available upon request.
9
with a comorbid psychiatric condition.11
For our main specification, we consider the individual treated if they fill a prescrip-
tion within a year of their ADHD diagnosis. Under this definition of treatment, males are
more likely to be treated with ADHD medication. Both females and males with combined-
ADHD take a higher intensity of treatment as shown by both the percentage of the sample
filling six or more prescriptions within a year and the average number of prescriptions
filled.12
Across gender and ADHD subtype classifications, the households primarily consist
of a single adult and two children. On average, individuals with PI-ADHD have a relatively
higher reported monthly household income than individuals with combined ADHD. In-state
birth certificates are matched to 73% of children in our sample providing data on mother’s
education and age when she gave birth.13 The majority of mothers in the sample have only
some high-school education (36.8%) or a high school diploma (40.1%).
Table 2.2 reports summary statistics on the academic performance measures used
in our analysis. Column (1) reports summary statistics by gender. Columns (2) and (3)
report summary statistics based on ADHD subtype classification and by gender. The test
score outcomes are defined as the probability of passing both the English and mathematics
examinations.14,15,16 We pool observations by grades to categorize test score outcomes in
terms of elementary school, middle school, and high school.17 For grade repetition, we
report summary statistics for each individual/school year. Means can be interpreted as the
11Common comorbid conditions associated with ADHD include oppositional defiant disorder, depression,
anxiety and bipolar disorder. The results are robust when we control for comorbid conditions that appear
prior the individual’s ADHD diagnosis.
12Average number of prescriptions filled is conditional on an individual filling at least one prescription
while observed in Medicaid.
13The number of observations matched with birth certificate data are represented by the number of
observations in parentheses.
14For elementary and middle school examinations, we observe the individual’s test score on a 1 to 5
rating. For high school examinations, we only observe if the individual passes or fails the exam. For ease
of interpretation, in our primary specification all test scores can be interpreted as the probability of passing
the English and mathematics examinations.
15For individuals who take the exam more than once, we take their test score from their first attempt.
16Other subjects in the dataset include science, social studies and writing test scores (results available
upon request).
17Elementary school includes observations in third, fourth and fifth grade, and middle school includes






















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































percent of the sample that repeats a grade in a given year.
Compared to males, females perform better throughout their school careers in terms
of higher probability of meeting English and mathematics examination requirements and
lower rates of grade repetition. Nearly 6.4% of females repeat a grade and approximately
8% of males repeat a grade each year. Across gender and ADHD subtype classification, we
observe that aside from elementary school, females diagnosed with PI-ADHD perform better
on test scores than females diagnosed with combined-ADHD. Relative to males diagnosed
with combined-ADHD, males diagnosed with PI-ADHD perform better on test scores across
their school careers.
Table 1.2: Summary Statistics: Academic Performance Measures
All ADHD Sample Combined ADHD Pred Inatt ADHD
(1) (2) (3)
Female Male Female Male Female Male
Probability of passing English & mathematics
Elementary School Test Scores 0.412 0.411 0.417 0.409 0.396 0.418
N obs 20,238 39,743 14,860 31,071 5,378 8,672
Middle School Test Scores 0.338 0.303 0.335 0.302 0.347 0.307
N obs 16,985 31,254 11,636 23,114 5,349 8,140
High School Test Scores 0.553 0.486 0.540 0.475 0.575 0.509
N obs 2,770 4,503 1,783 3,117 987 1,386
Grade Repetition 0.064 0.081 0.064 0.080 0.064 0.081
N obs 61,292 117,610 44,256 90,572 17,036 27,038
Notes: Test scores are interpreted as the probability of passing both the English and mathematics examinations.
Observations are pooled by grades to categorize test score outcomes in terms of elementary school, middle school,




To estimate the causal relationship between academic performance and ADHD med-
ication, we estimate the following model using our subsample of individuals diagnosed with
ADHD:
Yi = α0 +α1Treatedi +Xiα2 +Motheriα3 +Familyiα4 +Locationiα5 +Y eartα6 +εi (1.1)
where Yi represents an academic performance measure; Treatedi takes a value of one if the
individual fills at least one ADHD prescription within a year of their ADHD diagnosis and
zero otherwise; Xi is a vector of individual-level observables which includes gender, race,
birth year, year of ADHD diagnosis, and comorbid psychiatric conditions;18 Motheri repre-
sents maternal education and maternal age of birth; Familyi includes controls for number
of children and adults in the household as well as family income; Locationi represents either
the county of diagnosis or school the individual is enrolled in at the time of the outcome,
Y eart represents the school year. Our main coefficient of interest is α1, which can be in-
terpreted as the mean difference in outcomes across the treated and non-treated ADHD
diagnosed groups.
Because ADHD medication is not randomly assigned to individuals, Treated is likely
correlated with ε: unobserved factors that make some individuals more likely to receive
treatment also influence their academic performance. For example, parental characteristics
such as more attentive parenting may increase the likelihood that a parent pursues treatment
for their child. Better outcomes for this child may reflect the attentive parenting rather
than the effect of ADHD medication.




Following Duggan (2005), Dalsgaard et al. (2014) and Chorniy and Kitashima
(2015), we instrument for ADHD medication treatment receipt using diagnosing providers’
propensity to prescribe. An individual’s probability of treatment receipt is dependent on
whether the individual is diagnosed by a relatively high-prescribing doctor or low-prescribing
doctor.
PropPrescdt,∼i =
N patients treateddt − 1 ∗ (Treatedidt = 1)
N patientsdt − 1
(1.2)
For each individual i, we construct doctor propensity to prescribe treatment by cal-
culating the fraction of other patients that receive treatment from individual i’s diagnosing
provider d in year t. Specifically, we subtract the focal individual’s treatment status (0,1)
from the number of patients treated with medication by doctor d in year t, and divide by
the total number of other patients diagnosed with ADHD by doctor d in year t.
In our Medicaid pharmaceutical claims data, we only observe prescriptions filled by
the individual. Thus, the diagnosing provider’s propensity to prescribe reflects both the
probability that the provider writes a prescription and the probability that the patient fills
the prescription (Dalsgaard et al. (2014)).19
Figure 2.2 shows the distribution of provider propensity to prescribe in our dataset.
Variation in physician propensity to prescribe can in part be explained by variation in
physicians’ views on the effectiveness of medication and severity of side effects. Stockl et al.
(2002) surveys 1,000 physicians who prescribe ADHD medication and finds considerable
variation in physicians perception regarding the severity of medication side effects, the
effectiveness of medication, and concerns about the medication being used for purposes
19Both the probability that a provider prescribes medication to the patient and the probability that the
patient fills the prescription, conditional on the provider’s engagement with the patient, is relevant variation
for our analysis.
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Figure 1.2: Distribution of Provider Propensity to Prescribe
Notes: The figure shows the distribution of the probability that a patient receives a prescription from
a particular physician in the year of their diagnosis based on the sample of 58,674 ADHD-diagnosed
patients enrolled in SC Medicaid in 2003-2013. Provider prescribing behavior varies from zero to one.
other than patient’s medical needs.20
The first stage equation measures the relationship between provider propensity to
prescribe and ADHD medication treatment receipt given by Equation 2.4.
Treatedi = δPropPrescdt,∼i +Xiγ1 +Motheriγ2 +Familyiγ3 +Locationiγ4 +Y eartγ5 +νi
(1.3)
where the instrument PropPrescdt, i is a patient-specific probability to receive a prescription
from the provider who diagnosis the individuals with ADHD, excluding the focal individual;
Xi, Motheri and Familyi are the same vector of controls listed above. Treatedi is equal
to one if the individual receives ADHD medication treatment within 365 days of their
ADHD diagnosis and zero otherwise.21 We include academic outcome measures that occur
20Physician prescribing practices were found to vary with the reimbursement mechanism (Dickstein, 2014)
and their individual preferences (Hellerstein (1998))
21For robustness, we redefine treatment as the fraction of Medicaid eligible years the individual takes
ADHD medication after their ADHD diagnosis. We use IV probit maximum likelihood models to obtain
estimates, reported in Table 12.
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a year or more after the individual’s ADHD diagnosis, assuring that treatment predates the
educational outcome. A required assumption is that doctor prescribing behavior only has
an effect on treatment receipt within a year of the individual’s ADHD diagnosis (and has
no effect on outside treatment channels).22
After estimating Equation 2.4, Equation 1.4 estimates the causal effect of ADHD
medication treatment on test scores and Equation 1.5 estimates the causal effect of ADHD
medication treatment on grade repetition.
TestScoreig = α0 +α1 ̂Treatedi +Xiα2 +Motheriα3+Familyiα4 +Locationig +Y earg +εi
(1.4)
The effects of ADHD medication on primary and secondary students’ test scores are mea-
sured by Equation 1.4. We utilize a cross-sectional analysis with individual i in grade g as
the unit of observation. TestScoreig represents the test score of individual i in grade g.23
̂Treatedi is the predicted treatment from Equation 2.4. α1 is the variable of interest and
can be interpreted as the effect of being treated within a year of the individual’s ADHD
diagnosis on the individual’s test score. Locationig is a control for the school the individual
attends in grade g, and Y earg is a school year control.
In Equation 1.5, we measure the effects of ADHD medication on grade repetition.
We make use of our panel data which allows us to control for the individual’s grade, school,
school year specific trends as well as other time-varying factors that could have an effect on
grade repetition.
Repeatgradeit = β0 +β1 ̂Treatedi +Xiβ2 +Zitβ3 +Locationit +Y eart +Gradet + εit (1.5)
where Repeatgradeit represents whether the individual repeated a grade in year t. One
important thing to note is that the instrument doctor propensity to prescribe is constructed
22Section 2.5 provides further discussion on the validity of our instrumental variable.
23Test score measures can be interpreted as the probability of passing both the English and mathematics
examinations.
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for the year of the individual’s ADHD diagnosis and is not time varying. Thus, ̂Treatedi
is the predicted treatment from Equation 2.4 as in the cross-sectional analysis. β1 is the
variable of interest and can be interpreted as the effect of being treated within a year of the
individual’s ADHD diagnosis on the probability of repeating a grade in a given year.
In Equations 1.4 and 1.5, the standard errors are clustered on provider ID to allow
for the possibility of correlation across observations for observations that share the same
diagnosing provider. Estimation of Equation 1.4 and Equation 1.5 will be consistent pro-
vided that PropPresci influences treatment and is uncorrelated with the error terms εi and
εit. We provide supporting evidence of our identification strategy in Section 2.5.
1.5 IV Validity
In order for our instrument to be valid, the instrument must both be a strong pre-
dictor of ADHD medication treatment receipt and also be uncorrelated with the unobserved
factors determining students’ academic performance.
1.5.1 First Stage Results
Table 1.3 reports the first stage results. Column (1) reports first stage results by
gender. Columns (2) and (3) report first stage results by ADHD subtype classification
and by gender. Covariates include: the individual’s gender, race, comorbid psychiatric
conditions diagnosed prior to the individual’s ADHD diagnosis, birth year, year of ADHD
diagnosis, school location controls, mother’s age and education, family income, number of
children and number of adults in the household. In column (1) the coefficients on provider
propensity to prescribe can be interpreted as a 10 percentage point increase in provider
propensity to prescribe increases the probability of ADHD medication treatment receipt
3.9 percentage points for females and 3.33 percentage points for males. The three columns
show that provider propensity to prescribe has explanatory power for treatment receipt for
all subsamples we investigate and does not suffer as a weak instrument.
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Table 1.3: First Stage Results
All ADHD Sample Combined ADHD Pred Inatt ADHD
(1) (2) (3)
Dependent Variable: ADHD Treatment Female Male Female Male Female Male
Provider Propensity to Prescribe 0.390*** 0.333*** 0.404*** 0.330*** 0.309*** 0.294***
(0.017) (0.012) (0.021) (0.014) (0.037) (0.027)
Race: Black -0.051*** -0.038*** -0.049*** -0.038*** -0.080*** -0.041**
(0.010) (0.007) (0.012) (0.008) (0.023) (0.016)
Hispanic -0.222*** -0.086*** -0.251*** -0.114*** -0.192** 0.033
(0.048) (0.030) (0.059) (0.035) (0.098) (0.066)
Other -0.057** -0.062*** -0.054** -0.064*** -0.035 -0.044
(0.022) (0.013) (0.026) (0.015) (0.051) (0.034)
School Controls Y Y Y Y Y Y
Mother & individual characteristics Y Y Y Y Y Y
R2 0.282 0.201 0.336 0.223 0.434 0.326
N 11,322 22,002 7,916 16,587 3,190 5,003
Notes: The dependent variable is an indicator equal to 1 if treated with ADHD medication within 365 days of
diagnosis. Coefficient estimates that are significant at 1%, 5%, and 10% level are denoted with ***, **, and *
respectively. Standard errors are in parentheses. They are clustered by individual’s provider who diagnosed them
with ADHD.
1.5.2 Exclusion Restriction
1.5.2.1 IV Correlation with Observables
The assumption that doctor propensity to prescribe is not correlated with the un-
observable determinants of academic outcomes cannot be tested. However, if we find a rela-
tionship between the instrument and an important set of observables, we may be concerned
that the instrument is also correlated with unobservables. As a check for the assumption
that our instrumental variable is uncorrelated with unobserved factors determining students’
academic performance, we conduct balancing tests by regressing the instrument provider
propensity to prescribe on a set of observables as presented in Equation 1.6.
PropPresci = α0 +Xiα1 +Motheriα2 + Familyitα3 + µit (1.6)
where X is a vector of child characteristics including psychiatric conditions that the in-
dividual was diagnosed with prior to their ADHD diagnosis, Mother represents mother
characteristics including the mother’s age when she gave birth and the mother’s education,
Family represents family characteristics in the year of the individual’s diagnosis including
number of adults and number of children in the household in addition to family net income.
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Table 1.4 presents estimated coefficients and F-tests of joint significance of these
covariates in each specification. If higher educated mothers choose relatively higher pre-
scribing physicians, unobserved mother characteristics correlated with mother’s education
could bias our results towards finding that medication has positive effects on children’s
academic performance. Column (1) reveals that doctor prescribing behavior is not corre-
lated with mother’s education or mother’s age when she gave birth. In column (2), we add
family composition and income controls and find that number of adults in a household and
family income is not correlated with doctor propensity to prescribe. We do find a small,
economically insignificant correlation between number of children in a household and doctor
propensity to prescribe. The interpretation of this coefficient is increasing the number of
children in a family from one to two is associated with an increase in doctor propensity to
prescribe of 0.27 percentage points. The coefficients on the mother’s characteristics, family
composition, and income are jointly insignificant.
We next consider the plausibility of individuals diagnosed with other psychiatric
conditions being more likely to visit physicians with relatively high propensity to prescribe
ADHD medication. Column (3) shows evidence that there is no correlation between an
individual having a psychiatric condition and doctor propensity to prescribe.24
Because most families on Medicaid are relatively poor, there is little income vari-
ation in this population group. As an alternative measure of income, column (4) includes
indicators for free lunch and reduced price lunch receipt. The results show that there is no
correlation between free or reduced price lunch receipt and doctor propensity to prescribe.
1.5.2.2 Placebo Test
The exclusion restriction would be violated if doctor propensity to prescribe has
an effect on individuals’ academic performance through an alternative channel, outside of
treatment receipt. For example, if relatively lower prescribing physicians are more likely
to suggest other academic interventions, it could lead to a downward bias in the effects of
24Psychiatric conditions are considered if the individual is diagnosed prior to their ADHD diagnosis.
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Table 1.4: Instrument Correlation with Observables
Dependent Variable: Doctor PTP (1) (2) (3) (4)
Mother’s educ: Less than HS -0.0003 -0.0008 -0.0008 -0.0004
(0.006) (0.006) (0.006) (0.006)
Some HS -0.0033 -0.0037 -0.0037 -0.0033
(0.003) (0.003) (0.003) (0.003)
Some college -0.0039 -0.0035 -0.0035 -0.0038
(0.004) (0.004) (0.004) (0.004)
College degree 0.0010 0.0016 0.0016 0.0016
(0.006) (0.006) (0.006) (0.006)
Mother’s age at birth -0.0002 -0.0002 -0.0002 -0.0002
(0.000) (0.000) (0.000) (0.000)
N adults 0.0023 0.0024 0.0014
(0.002) (0.002) (0.002)
N children 0.0028** 0.0028** 0.0026**
(0.001) (0.001) (0.001)
Family income -0.0025 -0.0025 –
(0.002) (0.002) –






County FE Yes Yes Yes Yes
N 41,099 41,099 41,099 41,099
Joint F-Stat (excluding county FE) 0.54 1.46 1.31 1.09
p-value 0.75 0.16 0.23 0.37
Notes: The dependent variable is the instrument provider propensity to prescribe. The omitted mother
educational category is mothers with a high school degree. Coefficient estimates that are significant at
1%, 5%, and 10% level are denoted with ***, **, and * respectively. Standard errors are in parentheses.
20
ADHD medication on academic performance.
We devise a placebo test by making use of a sample of South Carolina Medicaid
children who were never diagnosed with ADHD (labeled undiagnosed). Because the undiag-
nosed sample of children cannot receive ADHD medication treatment, we test to see if doctor
propensity to prescribe has a direct relationship with academic performance outcomes out-
side of the treatment receipt channel. For the undiagnosed sample, we first identify their
provider at age 8, which is the mean age of when an individual is diagnosed with ADHD in
our sample. We construct a measure of doctor propensity to prescribe ADHD medication
for an individual who never is diagnosed with ADHD by using that provider’s prescribing
patterns to ADHD patients. Table 1.5 reports results for the undiagnosed sample. For com-
parison, Table 1.5 also reports the reduced form regression coefficients for children diagnosed
with ADHD.
Referring to Panel A, for the sample never diagnosed with ADHD we find that doctor
propensity to prescribe ADHD medication is not correlated with elementary, middle school,
or high school test scores and has no relationship with grade repetition. These findings
suggest that the instrument doctor propensity to prescribe has no direct effect (outside of
treatment receipt) on academic outcomes for the undiagnosed sample who cannot receive
ADHD medication. In comparison, Panel B shows that the reduced form estimates, that
regress academic outcomes on doctor propensity to prescribe for the ADHD sample, show
a negative correlation for female’s middle school and high school test scores. The reduced
form estimates also show a positive relationship between doctor propensity to prescribe
and grade repetition. The results are suggestive evidence in favor of doctor propensity to
prescribe as a valid instrument.
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Table 1.5: Placebo Test
Elementary Test Scores Middle School Test Scores High School Test Scores Grade Repetition
Female Male Female Male Female Male Female Male
Panel A. Undiagnosed Sample
Doctor Propensity to Prescribe 0.011 0.011 0.031 0.028 0.040 0.038 -0.003 0.002
(0.022) (0.024) (0.026) (0.029) (0.037) (0.040) (0.003) (0.004)
Race: Black -0.191*** -0.225*** -0.165*** -0.236*** -0.134*** -0.193*** 0.004** 0.009***
(0.012) (0.013) (0.015) (0.017) (0.020) (0.022) (0.002) (0.002)
Hispanic -0.037 -0.081** -0.025 0.011 0.020 0.053 -0.004 -0.009
(0.038) (0.039) (0.052) (0.056) (0.055) (0.071) (0.006) (0.007)
Other -0.053* -0.035 -0.124*** -0.063 -0.015 -0.087* 0.004 -0.005
(0.032) (0.033) (0.045) (0.048) (0.052) (0.052) (0.005) (0.006)
N child -0.014*** -0.004 -0.020*** -0.004 -0.011 0.014 0.003*** 0.004***
(0.005) (0.005) (0.006) (0.007) (0.007) (0.009) (0.001) (0.001)
Free lunch -0.009 -0.055*** -0.037** -0.039* 0.007 0.016 0.002 0.001
(0.016) (0.017) (0.018) (0.021) (0.021) (0.025) (0.002) (0.003)
Mean 0.625 0.574 0.523 0.454 0.732 0.674 0.026 0.039
N obs. 9,896 8,947 6,253 5,140 2,759 2,288 50,030 42,455
R2 0.162 0.168 0.188 0.199 0.191 0.235 0.129 0.155
Panel B. ADHD Diagnosed Sample
Doctor Propensity to Prescribe -0.020 0.005 -0.095*** 0.005 -0.100*** -0.004 0.014*** 0.008**
(0.018) (0.014) (0.020) (0.014) (0.031) (0.028) (0.005) (0.004)
Race: Black -0.198*** -0.196*** -0.188*** -0.196*** -0.167*** -0.192*** 0.014*** 0.012***
(0.011) (0.008) (0.012) (0.008) (0.020) (0.017) (0.003) (0.003)
Hispanic -0.067 -0.071* 0.100 -0.071* -0.055 0.010 -0.043*** -0.004
(0.050) (0.042) (0.076) (0.042) (0.101) (0.068) (0.015) (0.013)
Other -0.069*** -0.107*** -0.067** -0.107*** -0.090* -0.149*** 0.007 0.015**
(0.026) (0.015) (0.026) (0.015) (0.048) (0.034) (0.008) (0.006)
N child -0.011** -0.009*** -0.006 -0.009*** -0.009 -0.005 0.004*** 0.004***
(0.005) (0.003) (0.005) (0.003) (0.009) (0.007) (0.001) (0.001)
Free lunch -0.028 -0.061*** -0.043** -0.061*** -0.030 -0.057*** -0.004 0.003
(0.017) (0.013) (0.017) (0.013) (0.028) (0.022) (0.004) (0.004)
Mean 0.406 0.403 0.322 0.290 0.560 0.498 0.060 0.077
N 14,071 29,185 12,340 29,185 2,693 4,365 45,659 89,478
R2 0.145 0.151 0.153 0.151 0.193 0.179 0.209 0.216
Notes: Panel A and B show results of the placebo IV validity test. The dependent variable in each specification is one of the
academic outcomes. In Panel A, provider propensity to prescribe is constructed using the undiagnosed individual’s provider at
the mean age of an ADHD diagnosis. Panel B reports the reduced form coefficients (for the sample of individuals diagnosed with
ADHD). Coefficient estimates that are significant at 1%, 5%, and 10% level are denoted with ***, **, and * respectively. Standard
errors are in parentheses.
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1.6 Results
We first examine the effects of ADHD medication treatment by gender in Section
1.6.1. Table 1.6 reports the coefficients of ADHD medication treatment on elementary, mid-
dle, and high school test scores and Table 1.7 reports the coefficients of ADHD medication
treatment on grade repetition by gender.
We next stratify the sample by gender and ADHD subtype (see Section 1.2.1). Table
1.8 reports the coefficients of ADHD medication treatment on elementary, middle, and high
school test scores and Table 1.9 reports the coefficients of ADHD medication treatment on
grade repetition by gender and symptoms. Figures 1.3 and 1.4 plot the effects of ADHD
medication treatment on test scores for each individual grade (for elementary and middle
school) to determine if a particular grade year is driving the results and to observe the
effects of medication over the progression of the individual’s school career. The results are
presented in Figure 1.3 and Figure 1.4 for combined hyperactive/inattentive ADHD and
predominantly inattentive ADHD samples, respectively.
To summarize the results, we pool observations by grades to categorize test score
outcomes in terms of elementary, middle and high school.25 In these regressions, school
year and the individual’s grade are used as controls. For ease of interpretation, the test




Table 1.6 presents the results of ADHD medication treatment on elementary, middle,
and high school test scores for females (Panel A.) and males (Panel B.). The estimates
show that females who take ADHD medication are less likely to pass both the English
25Elementary school includes observations in third, fourth and fifth grade, and middle school includes
observations in sixth, seventh and eighth grade.
26For elementary and middle school examinations, we observe the individual’s test score on a 1 to 5
rating. Results on English, mathematics and science test scores are reported in Table 6 in the appendix.
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and mathematics examinations by 18 percentage points in middle school and 17 percentage
points in high school. However, the estimated coefficients on ADHD medication treatment
are small in magnitude and are not statistically significant for male students.
Appendix Tables 7 and 8 report the estimated coefficients of individual, mother, and
family controls. The coefficients are the expected signs and are similar for females and males.
Across elementary, middle and high school, black children are 17.1-20.1 percentage points
less likely to pass both the English and mathematics examinations relative to white children.
We control for comorbid psychiatric conditions that children are diagnosed with prior to
their ADHD diagnosis. We find that children diagnosed with a psychiatric condition are
4.4-11 percentage points less likely to pass their examinations. The largest negative effect
is for females in high school. Individuals in a household with a greater number of children
perform slightly worse on their test scores and this effect appears to be largest in elementary
school. For instance, going from a household with 1 to 2 children reduces the probability of
passing both the English and mathematics examination by 0.7-1.1 percentage points. This
is likely due to the fact that families with more children devote relatively less time to the
individual child. Finally, children who have mothers with lower levels of education perform
relatively worse on examinations.
1.6.1.2 Grade Repetition
Table 1.7 reports the results of ADHD medication treatment on grade repetition for
females and males. Each school year, approximately 6% of females diagnosed with ADHD
repeat a grade and 7.7% of males diagnosed with ADHD repeat a grade.27 The results
suggest that for students who take pharmaceutical treatment, the probability of repeating
a grade increases by 2.8 percentage points for females and 1.9 percentage points for males
in a given year.
The coefficients on covariates of interest are of expected signs and are similar across males
and females. Blacks are more likely than whites to repeat a grade. Controlling for English
27In the undiagnosed Medicaid sample, we observe that 2.6% of females repeat a grade and 3.9% of males
repeat a grade.
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Table 1.6: ADHD Treatment Effects on Test Scores by Gender
Elementary School Middle School High School
OLS IV OLS IV OLS IV
Panel A. Female:
Treatment -0.061*** -0.047 -0.090*** -0.180*** -0.075*** -0.170***
(0.011) (0.040) (0.012) (0.034) (0.019) (0.053)
Mean 0.406 0.322 0.560
N obs. 14,071 12,340 2,693
R2 0.148 0.148 0.158 0.150 0.195 0.233
Panel B. Male:
Treatment -0.001 0.014 -0.042*** -0.036 -0.027 0.002
(0.007) (0.037) (0.009) (0.034) (0.016) (0.057)
Mean 0.403 0.290 0.498
N obs. 29,185 23,924 4,365
R2 0.151 0.151 0.136 0.136 0.179 0.178
Notes: The coefficient estimates in this table can be interpreted as the effect of ADHD medication within
a year of the individual’s ADHD diagnosis on the probability of passing both the English and mathematics
examinations. All specifications include school controls, birth year, year of diagnosis, and school year
controls. We also control for the individual’s grade, comorbid psychiatric conditions, if the individual is
English proficient, mother’s age and education at birth, family income, number of children and adults in the
household, and number of patients diagnosed by the individual’s diagnosing provider. Coefficient estimates
that are significant at 1%, 5%, and 10% level are denoted with ***, **, and * respectively. Standard errors
are in parentheses. They are clustered by individual’s provider who diagnosed them with ADHD.
proficiency, Hispanic females are less likely to repeat a grade than white females. For both
females and males, increasing children in the household from 1 to 2 increases the likelihood
of grade repetition by 0.4 percentage points. Children who have mothers with lower levels
of education are more likely to repeat a grade in a given year. Children who were diagnosed
with a mental condition prior to their ADHD diagnosis are more likely to repeat a grade and
the effect is larger for males (1.3 percentage points) than females (0.6 percentage points).
1.6.2 By Gender and ADHD Subtype
1.6.2.1 Test Scores
We next divide the sample by gender and ADHD subtype classification. Table 1.8
presents the OLS and IV estimates of ADHD medication treatment on elementary, middle
and high school test scores. The rows specify the sub-samples: females diagnosed with
combined inattentive and hyperactive/impulsive ADHD (Panel A.), males diagnosed with
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Table 1.7: ADHD Treatment Effects on Grade Repetition by Gender
Female Male
OLS IV OLS IV
Treatment 0.016*** 0.028*** 0.005** 0.019**
(0.003) (0.009) (0.002) (0.009)
Race: Black 0.014*** 0.015*** 0.012*** 0.012***
(0.003) (0.003) (0.003) (0.003)
Hispanic -0.042*** -0.039** -0.002 -0.000
(0.016) (0.015) (0.012) (0.012)
Other 0.006 0.007 0.015*** 0.016***
(0.008) (0.008) (0.006) (0.006)
Num children in HH 0.004** 0.004** 0.004*** 0.004***
(0.001) (0.001) (0.001) (0.001)
Mother’s Educ: Less than HS 0.019*** 0.019** 0.014** 0.014**
(0.007) (0.007) (0.006) (0.006)
Some HS 0.011*** 0.011*** 0.008*** 0.008***
(0.003) (0.003) (0.003) (0.003)
Some college -0.013*** -0.013*** -0.007** -0.007**
(0.004) (0.004) (0.003) (0.003)
College degree -0.007 -0.008 -0.007 -0.006
(0.007) (0.007) (0.005) (0.005)
Mental condition 0.006** 0.006* 0.013*** 0.013***
(0.003) (0.003) (0.002) (0.002)
English proficient -0.042** -0.043** -0.012 -0.012
(0.018) (0.018) (0.014) (0.014)
Mean 0.060 0.077
N 45,659 89,478
R2 0.208 0.207 0.215 0.214
Notes: The coefficient estimates in this table can be interpreted as the effect of ADHD medication within
a year of the individual’s ADHD diagnosis on the probability of repeating a grade in a given year. All
specifications include school controls, birth year, year of diagnosis, and school year controls. We also
control for the individual’s grade, comorbid psychiatric conditions, if the individual is English proficient,
mother’s age and education at birth, family income, number of children and adults in the household,
and number of patients diagnosed by the individual’s diagnosing provider. Coefficient estimates that are
significant at 1%, 5%, and 10% level are denoted with ***, **, and * respectively. Standard errors are in
parentheses. They are clustered by individual’s provider who diagnosed them with ADHD.
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combined inattentive and hyperactive/impulsive ADHD (Panel B.), females diagnosed with
predominantly inattentive ADHD (Panel C.), and males diagnosed with predominantly
inattentive ADHD (Panel D.).28
We find that ADHD medication has negative effects for the subset of females diag-
nosed with combined inattentive hyperactive/impulsive ADHD (combined-ADHD). Specif-
ically, we find that ADHD medication decreases the probability of passing both the English
and mathematics exams by 20.2 percentage points in middle school and 19 percentage points
in high school. For males diagnosed with predominantly inattentive ADHD (PI-ADHD),
we find evidence that ADHD medication is beneficial in elementary school increasing the
probability of passing both the English and mathematics exams by 17.8 percentage points.
Interestingly, for males diagnosed with PI-ADHD we find no statistically significant effect
of ADHD medication in middle school or high school suggesting that the effects of ADHD
medication subside over these individuals’ school career.
1.6.2.2 Test Scores by Grade
We next analyze the effects of ADHD medication on test score performance by
running the regressions by grade to determine if the positive or negative effects of medication
are driven by observations in a particular grade and to observe the effects of medication over
the progression of the individual’s school career. Human capital accumulation theory would
predict that if ADHD medication improves academic performance, those improvements
would carry into subsequent grades. Figure 1.3 and Figure 1.4 plot the coefficient estimates
and confidence intervals of ADHD medication effects on the probability of passing the
English and mathematics tests across grades.
Figure 1.3 presents the effects of ADHD medication treatment for females and
males diagnosed with combined hyperactive/inattentive ADHD. The plot shows that ADHD
medication impedes academic performance for females diagnosed with combined hyperac-
tive/inattentive ADHD and the magnitude of the negative effect increases with each sub-
28For third through eighth grade, we have information on individual’s test score for English, math, and
science. Table 6 in the appendix reports the effects of ADHD medication on test scores broken up by subject.
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Table 1.8: ADHD Treatment Effects on Test Scores by Gender and Subtype
Elementary School Middle School High School
OLS IV OLS IV OLS IV
Panel A. Female Combined-ADHD:
Treatment -0.059*** -0.046 -0.104*** -0.202*** -0.070*** -0.190***
(0.013) (0.043) (0.015) (0.040) (0.022) (0.065)
Mean 0.408 0.320 0.548
N obs. 10,167 8,240 1,685
R2 0.247 0.247 0.230 0.222 0.312 0.302
Panel B. Male Combined-ADHD:
Treatment 0.001 -0.024 -0.039*** -0.060 -0.037* 0.019
(0.009) (0.039) (0.009) (0.037) (0.019) (0.057)
Mean 0.402 0.291 0.489
N obs. 22,398 17,267 2,939
R2 0.207 0.207 0.181 0.181 0.265 0.263
Panel C. Female PI-ADHD:
Treatment -0.087*** -0.164 -0.070*** -0.132 -0.114*** -0.066
(0.022) (0.108) (0.022) (0.081) (0.037) (0.116)
Mean 0.393 0.324 0.582
N obs. 3,537 3,805 962
R2 0.377 0.374 0.267 0.265 0.383 0.382
Panel D. Male PI-ADHD:
Treatment -0.008 0.178** -0.059*** -0.005 -0.006 -0.045
(0.018) (0.083) (0.021) (0.083) (0.031) (0.132)
Mean 0.411 0.292 0.517
N obs. 6,122 6,187 1,351
R2 0.289 0.270 0.211 0.209 0.288 0.287
Notes: Combined-ADHD represents the sample of individuals diagnosed with combined inattentive and hyperac-
tive/impulsive ADHD (Panels A. & B.). PI-ADHD represents the sample of individuals diagnosed with predomi-
nantly inattentive ADHD (Panels C. & D.). The coefficient estimates in this table can be interpreted as the effect of
ADHD medication within a year of the individual’s ADHD diagnosis on the probability of passing both the English
and mathematics examinations. All specifications include school controls, birth year, year of diagnosis, and school
year controls. We also control for the individual’s grade, comorbid psychiatric conditions, if the individual is English
proficient, mother’s age and education at birth, family income, number of children and adults in the household, and
number of patients diagnosed by the individual’s diagnosing provider. Coefficient estimates that are significant at
1%, 5%, and 10% level are denoted with ***, **, and * respectively. Standard errors are in parentheses. They are
clustered by individual’s provider who diagnosed them with ADHD.
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sequent grade, consistent with human capital accumulation theory. For females diagnosed
with combined hyperactive/inattentive ADHD, medication treatment reduces the probabil-
ity of passing both the English and mathematics examinations by 12.6 percentage points in
fifth grade, 17.1 percentage points in sixth grade, 19.5 percentage points in seventh grade,
and 28.1 percentage points in eighth grade. For males diagnosed with combined hyper-
active/inattentive ADHD, medication treatment appears to have no effect in 3rd through
6th grade. In 7th and 8th grade ADHD medication reduces the probability of passing the
English and mathematics examinations by 9.3 percentage points.
Figure 1.4 presents the effects of ADHD medication treatment for females and males
diagnosed with predominantly inattentive ADHD. The findings show that there are no con-
clusive effects of ADHD medication on females diagnosed with predominantly inattentive
ADHD, although in the majority of grades the coefficient is negative. On the other hand,
we find evidence that ADHD medication has beneficial effects for male students diagnosed
with predominantly inattentive ADHD in elementary school. For males with predominantly
inattentive symptoms, ADHD medication increases the probability of passing both the En-
glish and mathematics examinations by 21.4 percentage points in 3rd grade, 26.8 percentage
points in 4th grade, and 15.2 percentage points in 5th grade. The positive effects of ADHD
medication disappear in middle school.
1.6.2.3 Grade Repetition
Table 1.9 presents the effects of ADHD medication on grade repetition by gender and
ADHD symptoms. Considering ADHD medication has negative effects on the test scores
of females diagnosed with combined hyperactive/inattentive ADHD, it is not surprising
that medication increases the probability of grade repetition. If a female with combined
hyperactive/inattentive ADHD takes medication, they are 2.5 percentage points more likely
to repeat a grade in a given school year. For females with predominantly inattentive ADHD,
we find that the coefficient on ADHD medication is positive but not statistically significant.
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Figure 1.3: Effects of ADHD Medication on Test Scores over Grades
Notes: The figure plots the coefficient estimates and confidence intervals of the effects of ADHD
medication within a year of the individual’s ADHD diagnosis on the probability of passing both
the English and mathematics examinations by grade.
Figure 1.4: Effects of ADHD Medication on Test Scores over Grades
Notes: The figure plots the coefficient estimates and confidence intervals of the effects of ADHD
medication within a year of the individual’s ADHD diagnosis on the probability of passing both
the English and mathematics examinations by grade.
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For both males diagnosed with combined hyperactive/inattentive ADHD and males
diagnosed with predominantly inattentive ADHD, we find that ADHD medication increases
the probability of grade repetition by 1.8 percentage points in a given year. However, the
estimate is only statistically significant for the sample of males with combined hyperac-
tive/inattentive ADHD.
Table 1.9: ADHD Treatment Effects on Grade Repetition by Gender and Subtype
Combined-ADHD PI-ADHD
Female Male Female Male
OLS IV OLS IV OLS IV OLS IV
Treatment 0.013*** 0.025** 0.005** 0.018* 0.020*** 0.017 0.000 0.018
(0.004) (0.011) (0.003) (0.010) (0.006) (0.023) (0.005) (0.023)
Race: Black 0.014*** 0.015*** 0.012*** 0.013*** 0.014* 0.013* 0.017*** 0.017***
(0.004) (0.004) (0.003) (0.003) (0.007) (0.008) (0.006) (0.006)
Hispanic -0.035** -0.032* 0.009 0.011 -0.048 -0.048 -0.044* -0.044
(0.018) (0.018) (0.014) (0.014) (0.034) (0.034) (0.027) (0.027)
Other 0.007 0.008 0.013* 0.014** -0.005 -0.005 0.030** 0.030**
(0.010) (0.010) (0.007) (0.007) (0.017) (0.017) (0.013) (0.013)
Num children in HH 0.005*** 0.005*** 0.004*** 0.004*** 0.001 0.001 0.001 0.001
(0.002) (0.002) (0.001) (0.001) (0.003) (0.003) (0.002) (0.002)
Mother’s Educ: Less than HS 0.025*** 0.024*** 0.006 0.006 0.011 0.011 0.024* 0.024*
(0.008) (0.008) (0.017) (0.017) (0.007) (0.007) (0.012) (0.013)
Some HS 0.011*** 0.011*** 0.011 0.011 0.007** 0.007** 0.005 0.005
(0.004) (0.004) (0.007) (0.007) (0.003) (0.003) (0.005) (0.005)
Some college -0.009** -0.009* -0.018** -0.018** -0.008** -0.008** -0.011 -0.010
(0.005) (0.005) (0.008) (0.008) (0.003) (0.003) (0.007) (0.007)
College degree -0.003 -0.003 -0.033*** -0.033*** -0.007 -0.006 -0.016 -0.015
(0.008) (0.008) (0.013) (0.013) (0.006) (0.006) (0.010) (0.010)
Mental condition 0.005 0.005 0.007 0.007 0.013*** 0.013*** 0.013*** 0.013***
(0.003) (0.003) (0.006) (0.006) (0.003) (0.003) (0.005) (0.005)
English proficient -0.037* -0.038* -0.029 -0.028 -0.000 -0.000 -0.068** -0.071**
(0.020) (0.020) (0.040) (0.041) (0.015) (0.015) (0.032) (0.032)
Mean 0.060 0.077 0.059 0.075
N obs. 32,081 67,033 12,387 20,319
R2 0.218 0.218 0.220 0.220 0.301 0.301 0.270 0.269
Notes: Combined-ADHD represents the sample of individuals diagnosed with combined inattentive and hyperac-
tive/impulsive ADHD. PI-ADHD represents the sample of individuals diagnosed with predominantly inattentive
ADHD. The coefficient estimates in this table can be interpreted as the effect of ADHD medication within a year
of the individual’s ADHD diagnosis on the probability of repeating a grade in a given year. All specifications
include school controls, birth year, year of diagnosis, and school year controls. We also control for the individ-
ual’s grade, comorbid psychiatric conditions, if the individual is English proficient, mother’s age and education at
birth, family income, number of children and adults in the household, and number of patients diagnosed by the
individual’s diagnosing provider. Coefficient estimates that are significant at 1%, 5%, and 10% level are denoted
with ***, **, and * respectively. Standard errors are in parentheses. They are clustered by individual’s provider
who diagnosed them with ADHD.
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1.7 Robustness
We perform a number of robustness checks, reported in Table 2.7. First, we test
the sensitivity of our results when we control for provider specialty. In our dataset, we
observe that providers report different specialties on Medicaid claims. Due to switching,
choosing a provider’s specialty at one time period may not be a reliable measure of the
provider’s true specialty. However, neglecting to control for provider specialty could violate
the exclusion restriction. For example, the exclusion restriction could be violated if doctor
propensity to prescribe is correlated with provider specialty and if provider specialty has
a direct effect on individuals’ academic performance. To address this concern, we use the
provider’s declared specialty at the time of the individual’s ADHD diagnosis and find that
the results are robust. ADHD medication has adverse effects for females diagnosed with
combined-ADHD reducing the probability of passing test scores by 9.9 percentage points
in middle school and 20.9 percentage points in high school. On the other hand, ADHD
medication increases the probability of passing elementary test scores by 20.2 percentage
points for males diagnosed with PI-ADHD.
For our primary specification, we follow Dalsgaard et al. (2014) and include providers
that diagnose two or more patients a year. On average, the providers in our sample diagnose
37 patients per year with ADHD. Following discussion in Doyle (2007), Heckman (1981)
and Greene et al. (2001) consider small sample sizes per group to allow for meaningful
estimates, with a rule of thumb of eight observations per group. For robustness, we condition
on providers diagnosing at least eight patients. For females with combined-ADHD, we
find that the effects of ADHD medication on middle school and high school performance
are nearly unchanged. Interestingly, when conditioning on diagnosing providers to have
diagnosed at least eight patients, the positive coefficient on treatment shrinks and is no
longer statistically significant for elementary male students with PI-ADHD. Furthermore,
the negative coefficients on treatment become precise for combined-ADHD males’ middle
and high school test scores, as well as PI-ADHD females’ elementary school test scores,
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suggesting that medication could have further adverse effects. The estimates show that
males with combined-ADHD are 6.7 and 6.2 percentage points less likely to pass the middle
and high school exams and females with PI-ADHD are 14.7 percentage points less likely to
pass the elementary exams.
Ideally, we would like to control for special educational services that the individual
may receive. If low prescribing providers are more likely to encourage parents to seek special
educational services through their school, our results could be biased. Although we do not
have information on special educational services, the Department of Education data include
information on whether the individual has a registered learning disability. We use learning
disability registered through the individual’s school because in order for a student to enroll
in special educational services, they must have a registered learning disability. We exclude
this in our preferred specification because we are unable to observe the type of learning
disability or when the individual was diagnosed with the learning disability. Our results are
robust when we control for learning disabilities: females with combined-ADHD who receive
treatment are 17.4 percentage points less likely to pass the middle school exams and 15.6
percentage points less likely to pass the high school exams. Elementary male students with



























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































1.8 Discussion and Conclusions
With the rise of attention-deficit/hyperactivity disorder (ADHD) diagnoses and the
evidence that children with ADHD perform worse academically, a natural question that
arises is if ADHD medication improves students’ academic performance. This paper ana-
lyzes the effects of ADHD medication on children and adolescents’ educational outcomes
using variation in physicians’ prescribing rates of ADHD medication.
This study uses a unique data set of South Carolina Medicaid claims data merged
with academic outcomes. The data allow us to identify the individual’s ADHD subtype
based on symptoms: predominantly inattentive versus combined inattentive and hyperac-
tive/impulsive symptoms. To our knowledge, our study is the first to consider heterogenous
treatment effects by gender and ADHD subtype: 1) females with combined inattentive
and hyperactive/impulsive ADHD, 2) females with predominantly inattentive ADHD, 3)
males with combined inattentive and hyperactive/impulsive ADHD, and 4) males with pre-
dominantly inattentive ADHD. The estimates suggest that ADHD medication has mostly
adverse effects on academic performance. If treated with ADHD medication, males and fe-
males are more likely to repeat a grade. We find that ADHD medication makes females with
combined inattentive and hyperactive/impulsive ADHD less likely to pass middle and high
school state standardized tests.29 The only evidence we find of ADHD medication having
beneficial effects are for elementary school males diagnosed with predominantly inattentive
ADHD, but these effects vanish by middle school.30
Our results are consistent with the Currie et al. (2014) study. Because we observe
if and when an individual takes ADHD medication, a contribution of our study is that we
can directly measure the effect of ADHD medication on academic measures. Further, we
have more detailed education data providing us with a rich set of outcome measures and
controls.
29Treated females with combined inattentive and hyperactive/impulsive ADHD perform worse in elemen-
tary school when we use test scores by subject. See Table 6.
30This result is not robust when we condition on the individual’s diagnosing provider diagnosing at least
8 patients. See Table 2.7.
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A limitation of our study is that we are unable to identify the mechanisms by which
why ADHD medication has negative effects on academic performance. In our sample,
individuals diagnosed with combined inattentive and hyperactive/impulsive ADHD take
statistically higher dosages of medication which could increase the likelihood of side effects
(see Table 3.2). One plausible explanation is that the side effects of ADHD medication
such as depression, headaches, loss of appetite and sleep deprivation, may impede academic
performance.
Hinshaw et al. (2012) studies 140 females diagnosed with ADHD and finds that
they face a high risk of internalizing, and even self-harmful behavior patterns. The risk
is even higher for females diagnosed with combined inattentive and hyperactive/impuslive
ADHD. Barkley (2006) discusses several studies that show that children with both ADHD
and anxiety or affective disturbance are more likely to show adverse responses to medication
(Taylor, 1993; Voelker, Lachar & Gdowski, 1983; Pliszka, 1987). In our data we find that
both females and males with combined inattentive and hyperactive/impulsive ADHD have
statistically higher prevalence of comorbid psychiatric conditions. In our study we control
for comorbid psychiatric conditions that the individual was diagnosed with prior to their
ADHD diagnosis, but we believe more research should be devoted to looking at the effects
of ADHD medication when taken simultaneously with other medications.
Although we find mostly negative affects of ADHD medication on academic per-
formance, Chorniy and Kitashima (2015) and Dalsgaard et al. (2014) find that ADHD
medication is beneficial for behavioral outcomes. Specifically, the findings of these studies
suggest that ADHD medication reduces the probability of risky sexual behavior, substance
abuse, and injuries and to some extent protects against criminal outcomes. Combining
these findings with the findings in this study, it appears that ADHD medication may be
effective in improving behavioral outcomes but harms academic performance for a subset
of the population. It is worth noting that we are unable to generalize our results to the
non-Medicaid population. However, the Medicaid population has relatively lower academic
achievement and is at higher risk of negative health outcomes. Given the evidence of these
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Sex, Drugs, and ADHD: The Effects of ADHD
Pharmacological Treatment on Teens’ Risky
Behaviors (with Anna Chorniy)
2.1 Introduction
Attention-deficit/hyperactivity disorder (ADHD) is one of the common chronic men-
tal conditions affecting children. In the U.S., 11% of children ages 4-17 (6.4 million) are
estimated to have an ADHD diagnosis and almost 70% of them report taking medication
for the condition (e.g. Visser et al. (2014)). However, little evidence exists on the effects of
ADHD treatment on children’s outcomes.
The two most recently published studies produce mixed evidence on the effects of
ADHD treatment. Currie et al. (2014) find that taking stimulant medication is associated
with a deterioration in academic outcomes and relationship with parents. In contrast,
Dalsgaard et al. (2014) show that treatment is associated with fewer hospital visits and a
reduction in the number of interactions with the police.
Our paper has three major contributions to this literature. First, we are building
on our earlier work to investigate the effects of ADHD medication treatment on a seldom
studied set of outcomes associated with this condition: adolescent risky behaviors and the
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incidence of injuries (Chorniy (2015)). The occurrence of injuries allows us to evaluate
short-term effects of ADHD treatment, while substance abuse and risky sexual behavior
outcomes speak for the long-term effects of medication. Second, we use Medicaid spending
on treatment of these negative events to evaluate the impact of ADHD drugs on the severity
of ADHD, and compare the cost of ADHD treatment with the costs of negative health events.
Finally, we provide innovative supporting evidence in favor of using provider propensity to
prescribe as an instrument for medical treatment. Variants of this instrument were employed
in the work by Dalsgaard et al. (2014) and Duggan (2005), as discussed in Section 2.5.
We use a panel data set of South Carolina Medicaid claims paid out in 2003-2013.
Our sample of diagnosed and undiagnosed children includes an average of 257,000 enrollees
per year, or nearly 50% of all beneficiaries and over 25% of all SC children and teens. Chil-
dren enrolled in SC Medicaid are disproportionately diagnosed with ADHD. It is consistent
with the earlier literature that suggests that the probability of being diagnosed with ADHD
is negatively correlated with socio-economic status (e.g. Visser et al. (2014), Froehlich
et al. (2007), and Dalsgaard et al. (2014)). Between 2003 and 2011, the average incidence of
ADHD in South Carolina was 12.6%.1 However, for children and teens enrolled in Medicaid,
the average rate in these years was 19.7%. Although we are unable to make a statement
on the effectiveness of ADHD treatment in general population, our sample represents a
large fraction of the state population, and even larger fraction of diagnosed children. Since
children on Medicaid are disproportionately diagnosed with ADHD and their incentives are
distorted in the absence of a drug price tag, this population is arguably more appropriate
for this study from a policy perspective.
Nearly 80% of SC Medicaid children and teens who are diagnosed with ADHD are
taking medication for their condition. Consistent with the national trend, our data also
show a steep increase in Medicaid spending on ADHD prescription drugs. Between 2003
and 2013, it rose by 296% in 2013 dollars. This increase in spending is a consequence of both
the increase in the number of prescriptions filled and the prices of the drugs. The number
1CDC. “Trends in the Parent-Report of Health Care Provider-Diagnosed and Medicated ADHD: United
States, 2003-2011.”
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of patients who take ADHD medications rose by 68% and the number of prescriptions per
person went up by 18% suggesting that the overall trend is driven by the extensive margin.2
Our results suggest that pharmacological treatment reduces the probability of every
negative health and behavioral outcome that we identified in the data. If a patient is
treated with ADHD medication the probability of contracting an STD decreases by 3.6
percentage points (5.8 percentage points if we include STD screening), having a substance
abuse disorder decreases by 7.3 percentage points, becoming injured by 2.3 percentage points
each year and annual injury spending decreases by $88.4, or 0.054 of a standard deviation.3
Finally, the probability of teenage pregnancy decreases by 2.3 percentage points, though
the effect is not statistically significant.
2.2 Background and previous research
2.2.1 ADHD and ADHD-associated negative health outcomes
The American Psychiatric Association defines ADHD as a neurodevelopmental con-
dition present if either six or more of the inattention symptoms or six or more hyperactivity-
impulsivity symptoms “have persisted for at least 6 months to a degree that is maladaptive
and inconsistent with developmental level.”4 Inattentive symptoms include difficulty holding
attention on tasks, following instructions, and distractibility among others. Hyperactivity
and impulsivity criteria include excessive talking, difficulty waiting, and fidgeting. Causes
of ADHD are not fully understood but genes are recognized as a major determinant of the
condition.
ADHD may adversely impact major life activities from childhood to adulthood.
2There is some evidence of ADHD being increasingly misdiagnosed (e.g. Evans et al. (2010), Elder
(2010), Schwandt and Wuppermann (2015), and Morrill (2016) among others). This question is out of scope
of this paper. If there are false positive cases of ADHD diagnosis in our sample, our estimates of the effect of
ADHD treatment on negative health outcomes outcomes can be interpreted as a lower bound of the actual
effect of medication.
3In 2013 dollars.
4The American Psychiatric Association publishes the Diagnostic and Statistical Manual of Mental Dis-
orders (DSM), where it sets criteria for the classification of mental disorders. It is the standard classification
of mental disorders used by mental health professionals in the United States. The most current version is
DSM-5 published in May 2013, a revision of DSM-IV-TR that came out in 2000.
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Earlier studies have found that untreated ADHD could have severe consequences and be
distressing not only for children who suffer from the condition but also for their families
(Kvist et al. (2013), Fletcher and Wolfe (2009)), siblings (Breining (2014)), friends, peers
(Aizer (2008)), and teachers (Barkley (2006)). Children with ADHD tend to have prob-
lems with self-control and discount the future more heavily than their unaffected peers.
This makes them more injury-prone5 and more likely to engage in risky behaviors such
as: dangerous driving,6 substance use and abuse,7 and risky sexual behaviors.8 Children
growing up with ADHD were found to be more likely to experience teen pregnancy, sexually
transmitted diseases (STDs), depression, and personality disorders as adults.
These health and behavioral outcomes can be explained in the theoretical framework
of investment in child well-being. Every child is born with a multidimensional endowment of
abilities. They include cognitive (e.g. IQ, memory) and noncognitive skills (e.g. self-control,
patience, and time preference)(Conti and Heckman (2014)). Due to their genetic condition,
children who suffer from ADHD have a relatively low initial stock of noncognitive skills.
The literature on child development indicates that gaps in abilities that form early in life
persist into adulthood and can explain a large array of differentials in adult outcomes. Conti
5Besides having more frequent injuries, these children also tend to have more severe injuries than their
peers (Barkley (2006), Swensen et al. (2004), and Marcus et al. (2008)). In a recent study, Dalsgaard et al.
(2015) show that children with ADHD have a higher risk of injuries, but it declines in patients treated with
stimulant medications.
6One of the strongest findings in the medical literature is that ADHD adolescents are more likely be
involved in a car accident and they are more often at fault in such accidents (Barkley (2006), Weiss and
Hechtman (1993)).
7Looby (2008) provides a review of major studies on the association of ADHD and substance use and
abuse, including alcohol, tobacco, and drugs. Some of them find that teens with ADHD are on average
more likely than individuals without ADHD to smoke, use and abuse alcohol and drugs, and develop health
problems related to these activities. However, others conclude that there are additional related conditions
that contribute to the likelihood of these negative health outcomes, e.g. conduct disorder symptoms and
association with deviant peers. Despite a disagreement on the relationship between ADHD and substance
use, Looby (2008) review suggests that ADHD treatment reduces the risk of substance use disorders in
children with ADHD. Using a meta-analysis, Wilens et al. (2003) also find that stimulant medications
reduce the risk for subsequent drug and alcohol use disorders.
8Adolescents with untreated ADHD have difficulty controlling their impulses and planning ahead. These
teens also tend to struggle with low self-esteem and for that reason, teenage girls often seek affirmation of
boys through sexual attention (Arnold (1996)). Adolescent girls’ symptoms of ADHD often worsen due
to the hormonal changes at puberty (Resnick (2005)). Their condition makes them more likely to become
sexually active earlier than their peers, have more partners on average, and use birth control inconsistently
(Kessler et al. (1997), Payne (2014)). This association is also found in a more recent study by Sarver et al.
(2014).
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and Heckman (2014) provide an extensive review of the empirical evidence on the effects of
investment in the two dimensions of child human capital, cognitive and noncognitive skills,
on educational attainment, asocial and risky behaviors, and health. Heckman et al. (2006)
find that both cognitive and noncognitive abilities affect wages, schooling, work experience,
occupational choice, and participation in a range of adolescent risky behaviors. These results
have important policy implications, but most interventions do not directly target children’s
noncognitive abilities. The Perry Preschool experiment may be an exception; it did not
result in IQ improvements but instead had a beneficial impact on many child outcomes.
Heckman et al. (2006) argue that these beneficial impacts were achieved by altering social
skills.
In this paper, we focus on a variety of negative health outcomes associated with
ADHD: injuries, substance use, and risky sexual behavior. Injuries is the most common
outcome that affected 80% of children in our sample; it is relevant for children at all ages
and the average age is around the mean age of ADHD diagnosis (9 years old). Risky sexual
behavior and substance abuse outcomes are relevant for older children, with the average age
being 14-16 years old, or 6-8 years after most children are diagnosed with ADHD. In other
words, injury events allow us to evaluate short-term effects of ADHD treatment, while the
risky behavior related events speak for long-term treatment effects.
2.2.2 Prior Studies
An existing body of medical literature suggests that ADHD medication has positive
impacts on mitigating core symptoms of ADHD, yet little is known about the effects of
treatment on health, behavioral, and educational outcomes, particularly in the long run.
One of the major attempts to estimate the long-term effects of ADHD treatment in a
clinical setting was funded by the U.S. National Institute of Mental Health in the early
1990s. The Multimodal Treatment of Attention Deficit Hyperactivity Disorder (MTA) ran-
domly assigned 579 ADHD-diagnosed children age 7-9.9 years old to 14 months of treatment
management. The study finds that medication treatment alone and medication treatment
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combined with behavioral therapy reduces inattention and hyperactivity, the core symp-
toms of ADHD. However, there was little or no difference in academic performance, social
skills and parent-child relationships. An important limitation of the study is that nearly
70% of individuals assigned to the control group also received medication. Molina et al.
(2009) investigates the effects for these randomized treatment groups 6-8 years following
intervention. They find that the groups do not differ significantly on any repeated measures
or new measures of outcomes: contacts with the police and arrests, delinquent behavior,
social skills and academic performance.
Currie et al. (2014) take advantage of a policy change in Quebec which expanded
insurance coverage for prescription medications to estimate the effect of ADHD treatment
on emotional functioning and academic outcomes. Using data from the 1994-2008 National
Longitudinal Survey of Canadian Youth, they find that stimulant medication treatment is
associated with a decrease in academic outcomes such as grade repetition, math scores,
and the probability of having any post-secondary education for girls, a deterioration in
relationship with parents, and an increase in the probability of depression.
Dalsgaard et al. (2014) exploit the idiosyncratic differences in physician preferences
to prescribe pharmacological treatment to analyze the effects of ADHD treatment on hospi-
tal visits and criminal behavior. Consistent with Duggan (2005), they find that prescribing
practices vary significantly across medical care providers. This implies that two children
with identical symptoms and characteristics have a different probability of being diagnosed
and treated with medications depending on their physician’s preferences. Using Danish reg-
isters data and provider probability to prescribe as an instrument, Dalsgaard et al. (2014)
find that treatment receipt is associated with fewer hospital visits and fewer police interac-
tions.
In a recent study, using the same data these authors and a number of co-authors
estimate odds ratios for injuries, mean change in prevalence rates, and ER visits before and
after the treatment with stimulant medication (Dalsgaard et al. (2015)). They find that
children with ADHD have a higher risk of injuries than a non-ADHD group, but it declines
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in patients treated with stimulant medication.
We contribute to the existing literature in three ways. First, we look at a seldom
studied set of ADHD-related negative health outcomes: teenage pregnancies, incidence
of STDs, substance abuse disorders, and injuries. To our knowledge, this paper and its
dynamic model companion (Chorniy (2015)) are the first to directly study the effects of
ADHD treatment on these outcomes in health economics literature. Our general conclusions
on the effect of treatment on injuries are consistent with the medical literature (Dalsgaard
et al. (2015)); but we are not aware of any comparable studies on the other outcomes.
Second, we take advantage of Medicaid spending reported in the data to estimate
the impact of ADHD medication on the severity of injuries, STDs, and substance abuse
disorders. Medical treatment may be effective in reducing the severity of negative health
outcomes even if the likelihood of having one is unchanged. Medicaid expenditures are also
important from the policy perspective. In South Carolina, out-of-pocket costs for Medicaid
enrollees under 19 years old are zero or negligible. This distorts the patients’ incentives and
puts the burden of cost-benefit analysis on policymakers. Medicaid investment in ADHD
treatment might be balanced via a reduction in its spending on the ADHD-associated events.
We briefly examine this question in the current work and leave the detailed study to future
research.
Finally, we provide innovative supporting evidence in favor of using provider propen-
sity to prescribe as an instrument for medical treatment. Its variants were employed in the
work by Dalsgaard et al. (2014) and Duggan (2005). Our data allow us to construct a more
precise measure of provider preferences and test whether there is evidence of the instrument
being correlated with provider quality and whether there is evidence of provider shopping.




We use a large panel data set of South Carolina Medicaid claims that spans 11 years
from 2003 to 2013. It includes 145,264 children and teenagers who had at least one ADHD-
related claim between 3 and 18 years old during this time period. This sample makes up
approximately 20% of the child population in the state.
Our data include basic demographic information collected to determine Medicaid
eligibility and a complete set of health services utilization records for all individuals: hos-
pital, outpatient, and pharmacy claims.9 It is supplemented by several variables from the
enrollees’ birth certificates including mother’s age, race, and education. Following ear-
lier research work that used Medicaid or other administrative claims data (e.g. Frank
et al. (2004)), we compile a set of ICD-9 diagnosis codes10 and CPT procedure codes11 to
identify individuals who have ADHD, cases of pregnancy, STDs, substance use and abuse
disorders,12 and injuries13 from the insurance claims data. Administrative data are not
well-suited for distinguishing two consecutive independent events of the same kind from
continuous care for the same event. For this reason, we focus on the first occurrence of
each negative health outcome: teenage pregnancy, STD contraction, STD screening, and
substance use and abuse disorders. While we use the first observed negative health outcome
event to identify the incidence of negative health outcomes, we track all Medicaid spending
related to these events across time.14
9Medicaid has two components: traditional fee-for-service (FFS) and services provided through managed
care organizations (MCO). Due to the differences in reporting requirements, the complete information on
all services provided to a patient are only available for those enrolled in the FFS plan. However, mental
health is one of the “carved-out” conditions that is covered by the FFS component even if an individual is
enrolled into a managed care plan. We use all available claims and when possible, perform robustness checks
by excluding MCO enrollees.
10The International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes
are used by Medicaid for reporting purposes in the years covered by our sample. A hospital claim may have
up to 9 diagnosis codes and an outpatient claim may have up to 4 codes.
11The Current Procedural Terminology (CPT) codes are used to indicate services provided to a patient.
A hospital claim may have up to 100 procedure codes and an outpatient claim may have up to 8 codes.
12For substance use and abuse disorders we use a methodology developed in Bouchery et al. (2012).
13The ICD-9 codes for injuries were borrowed from Marcus et al. (2008).
14We disregard any out-of-pocket expenditures in this study. In 2013, most eligible individuals faced a
small copay per doctor visit ($3.30), per prescription ($3.40 for adults over 19 years old and zero otherwise),
and per hospital stay ($25).
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We use pharmacy claims to extract information on ADHD prescription medications
that were filled by a patient. Each record has a dispense date, National Drug code (NDC),15
quantity purchased, dispense fee, and the amount paid by Medicaid. We use our previous
work (Chorniy (2015)) to identify drugs that are typically prescribed to patients with ADHD
and to construct our instrumental variable (Section 2.4).
To estimate our model, we put a number of restrictions on the original data set.
First, we select individuals who are consistently enrolled for Medicaid for a year or more for
us to be able to estimate the effect of treatment. For lapses in enrollment that last under
three months, we assume that patients are enrolled but receive no medical treatment.16 For
inconsistent eligibility periods that result in longer lapses in coverage (48% of the enrollees
experience at least one such lapse), we only keep medical history prior to the lapse. These
criteria leave us with 107,062 Medicaid enrollees.
Second, due to the fact that our instrument is based on the event of the initial ADHD
diagnosis, we exclude individuals for whom we are unable to identify this event. Following
earlier literature (e.g. Crawford and Shum (2005)), we only look at patients who had their
first ADHD-related visit within 180 days from their first appearance in the sample and
patients who fill a prescription prior to their first observed ADHD-related provider visit.
This restriction excludes 29,974 additional individuals from the sample. Additionally, a
patient had to be diagnosed between 3 and 18 years old and be in the sample for at least
one full year since the event of the first ADHD diagnosis to be included in the analysis;
62,643 patients satisfied this criteria. Our final sample has 58,685 individuals after excluding
ADHD children with missing basic demographic information and children for whom we were
unable to calculate provider propensity to prescribe.17
Table 3.2 shows summary statistics on individual, mother, and home environment
15NDC is an 11-digit classification issued by the Food and Drug Administration (FDA) for all the approved
drugs.
16Once eligibility for Medicaid is established, the health insurance coverage is available for an enrollee for
a 12-month period (unless the enrollee becomes ineligible during this time), after which the eligibility needs
to be reconfirmed. An eligible individual who received services prior to the actual enrollment can be covered
retroactively for up to two months prior to the month when eligibility was established.
17We are unable to calculate a provider propensity to prescribe for providers who diagnose less than 2
patients with ADHD in a year.
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characteristics. Boys comprise 66% of the sample, similar to the proportion of boys (69%)
reported by the U.S. National Survey of Children’s Health in 2011 (Visser et al. (2014)).
Whites and Blacks are represented nearly equally, due to the relatively higher share of Black
on Medicaid. On average, children are first diagnosed with ADHD at 8 years old, and half
of them are diagnosed by age of 7. Given that the population we are looking at is slightly
older, this is generally consistent with the nationwide estimates. Among children age 4-17
years whose parents reported “mild” ADHD symptoms the median age of diagnosis is 7.0
years old, 6.1 years for those with “moderate” symptoms, and 4.4 years for “severe” cases
of ADHD (Visser et al. (2014)).
The families predominantly consist of a single adult and two children. Their reported
net monthly income is $574 on average. The majority of mothers in the sample have at
least some high-school education (37%) or a high school diploma (40%). Data on mother’s
characteristics comes from the in-state birth certificates (matched to 72% of children in our
sample).
In addition to the entire cohort of children on Medicaid who are diagnosed with
ADHD in SC between 2003-2013, we have a supplemental random sample of children on
Medicaid who were never diagnosed with ADHD.18 We use this sample to test the validity
of our identification strategy (see Section 2.5). Summary statistics for this group of children
are shown in the appendix (Table 17 and Table 18).
Table 2.2 reports summary statistics on ADHD medical treatment and ADHD-
related negative health outcomes that we observe in the sample. Nearly all children di-
agnosed with ADHD have attention-deficit disorder with hyperactivity (ICD-9: 314.01) as
opposed to disorder without hyperactivity (ICD-9: 314.00). In our primary specification, we
define pharmacological treatment as one or more prescriptions filled within a year of the in-
dividual’s ADHD diagnosis (72% of patients). We also introduce two alternative definitions
of treatment and results are reported in Section 2.10. We define treatment if we observe
an individual ever filling a prescription after their ADHD diagnosis (79% of patients), and
18It includes eligibility information, hospital, and outpatient claims for the undiagnosed children under
19 years old with higher weights assigned to relevant birth cohorts.
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following Dalsgaard et al. (2014) we define treatment as a period of at least six months on
medication in a given year (52% of patients).
On average, we observe every Medicaid enrollee for eight years. During this time,
1,811 girls become pregnant before age 19; 3,288 teens contract an STD and an additional
2,184 are tested for an STD condition. For 5,864 teens we observe at least one claim that
indicates a substance abuse disorder. The most frequent outcome that we observe yearly
are injuries. Of all ADHD-diagnosed children and teens, 80% have at least one injury while
in the sample.
In order to take into account the severity of negative health events, we calculate
the total Medicaid spending using the respective claims. The average annual cost of treat-
ment for an STD condition is $400 ($354 per patient if we include all patients who were
screened for an STD). The annual cost of a substance abuse condition, including spending
on prescribed medications is $1,499 per patient. Finally, the average cost of injuries per
person per year is $704. These expenditures vary widely across patients, costing Medicaid
thousands of dollars in the upper tail of the distribution.19
19All spending amounts are adjusted to 2013 dollars.
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Table 2.1: Summary Statistics: Individual and Family Characteristics
N obs. Mean Median SD Min Max
Individual characteristics
Age 1st in sample 58,685 4.12 3.00 4.04 0 18
Age at 1st ADHD diagnosis 58,685 7.98 7.00 3.46 3 18
Male 58,685 0.66 0 1
Race: White 58,685 0.47 0 1
Black 58,685 0.43 0 1
Hispanic 58,685 0.02 0 1
Family & home environment
Monthly family net income 58,685 573.94 408.80 584.93 0 5,189
Number of adults 58,685 1.03 1.00 0.59 0 3
Number of children 58,685 1.91 2.00 0.96 0 6
Ever in foster care 58,685 0.09 0 1
Ever had disability 58,685 0.15 0 1
Mother’s characteristics
Age when gave birth 42,488 23.41 22.00 5.47 11 48
Educ: Less than HS 42,488 0.05 0 1
Some HS 42,488 0.37 0 1
HS diploma 42,488 0.40 0 1
Some college 42,488 0.13 0 1
College degree or higher 42,488 0.05 0 1
Notes: The sample includes every SC Medicaid enrollee who was diagnosed with ADHD between 3 and 18 years
old in 2003-2013 and who was eligible for Medicaid for at least one year after this event. Family characteristics are
averaged per patient/eligibility year. Foster care and disability rates are calculated based on Medicaid enrollment
categories. Mother characteristics are reported based on in-state birth certificate information matched to Medicaid
records. They are available only for a subsample of the 42,488 patients. Mother’s age and educational attainment
are recorded at the time of the child’s birth. “HS” stands for high school education level.
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Table 2.2: Summary Statistics: Medical Treatment and Negative Health Outcomes
N obs. Mean Median SD Min Max
Medical diagnosis & treatment
1st diagnosis: ADD w/ hyperactivity 58,685 0.74 0 1
ADD w/o hyperactivity 58,685 0.24 0 1
1+ Rx filled within a year (1st diag) 58,685 0.72 0 1
1+ Rx filled (ever) 58,685 0.79 0 1
6+ Rx filled within a year (ever) 58,685 0.52 0 1
Annual cost of ADHD visit 58,685 586.75 152.10 1819.20 1 151,980
Annual cost of ADHD Rx 46,355 419.33 265.38 466.81 1 7,897
Years in sample 58,685 7.94 8.00 2.73 1 11
Outcome: Risky sexual behavior
1. Teen Pregnancy
Age at 1st pregnancy 1,811 16.67 17.00 1.75 11 19
Race: White 1,811 0.53 0 1
Black 1,811 0.43 0 1
2. STD
Age at 1st STD 3,288 14.46 14.00 2.49 11 19
Age at 1st STD (incl. screening) 5,472 14.80 15.00 2.33 11 19
Male 3,288 0.42 0 1
Race: White 3,288 0.57 0 1
Black 3,288 0.35 0 1
Annual cost of STD 3,288 399.84 152.32 1129.51 4 19,728
Annual cost of STD+test 5,472 353.88 181.80 777.86 2 19,728
Outcome: Substance Abuse
Age at 1st substance abuse 5,864 15.12 15.00 2.11 11 19
Male 5,864 0.64 0 1
Race: White 5,864 0.51 0 1
Black 5,864 0.42 0 1
Annual cost of substance abuse 5,864 1498.32 430.45 3640.24 1 113,834
Outcome: Injuries
Ever injured 58,685 0.80 0 1
Age at injury 46,730 9.07 8.50 3.72 3 19
Male 46,730 0.67 0 1
Race: White 46,730 0.50 0 1
Black 46,730 0.40 0 1
N of injury claims 58,685 0.37 0.27 0.44 0 12
Annual cost of injuries 46,730 704.37 247.10 4072.36 2 501,616
Notes: The sample includes every SC Medicaid enrollee who was diagnosed with ADHD between 3 and 18 years
old in 2003-2013 and who was eligible for Medicaid at least one year after this event. Alternative treatment
definitions are used for the robustness checks in Section 2.10. Annual cost of treatment and negative health
outcomes are given in 2013 dollars per patient/year conditional on treatment or the occurrence of a negative
health outcome. They are based on the Medicaid reimbursement payouts. The out-of-pocket patient costs are
nearly zero for the population in our sample.
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2.4 Empirical Model
2.4.1 Lifetime Effects of ADHD Treatment
We use a linear probability model to estimate the effects of ADHD medical treatment
on the incidence of adverse health and behavioral outcomes in adolescents who are diagnosed
with the condition. In this experiment, we compare the outcomes of treated and not treated
children with ADHD. We model outcomes as shown in Equation 2.1.
Yi = Xiβ + αiTreatmenti + γ1Countyi + γ2Y eari + εi, (2.1)
where Y represents one of the negative health outcomes that are common for individuals
diagnosed with ADHD, i: STD contraction and STD screening, substance use and abuse,
and teenage pregnancy. X is a vector of covariates that includes observed individual charac-
teristics (race, gender, birth year), net monthly family income at the first ADHD diagnosis,
patient age, and duration of enrollment.20 We also control for the location (county of pa-
tient’s residence at diagnosis) and the year of diagnosis. We exclude all individuals, treated
or untreated, who have experienced an adverse outcome (STD, STD test, substance abuse,
or pregnancy) prior to, or in the same year of, their ADHD diagnosis and estimate the
model using post-diagnosis medical history to assure that the adverse events do not deter-
mine the instrument. Note that an advantage of this strategy over the specification where
we would be looking at the occurrence of adverse events at a given age (e.g., at age 14), is
that we include patients who were diagnosed later in life, conditional on not experiencing
adverse events prior to the first diagnosis. This is particularly important for our long-term
outcomes that are relevant during patient teen years.
For STD, STD screening, substance abuse, and teenage pregnancy outcomes we
utilize a subsample of relevant birth cohorts of SC Medicaid enrollees. They are individuals
born between 1987 and 1996, whose teen years overlap with our sample period and who
are enrolled in Medicaid for at least one year during this time. Treatment takes a value of
20The length of the time period the individual was enrolled in Medicaid between 2003 and 2013.
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one if the individual fills at least one ADHD prescription within the year of their ADHD
diagnosis, as described in Section 2.3.
The parameter of interest in this equation is α. In the linear probability model
framework, it can be interpreted as the average impact of being treated within the year of the
individual’s ADHD diagnosis on the likelihood of negative health outcomes in adolescence.
Equation 2.1 can be rewritten to reflect two potential sources of bias:
Yi = Xiβ + ᾱT reatmenti + Treatmenti(αi − ᾱ) + γ1Countyi + γ2Y eari + εi (2.2)
First, if Treatment is correlated with ε, unobserved factors that make some individ-
uals more likely to receive treatment also influence their health and behavioral outcomes.
For example, relatively more caring parents might be more likely to pursue medical treat-
ment for their child. These parents are also more likely to take measures to reduce the
probability of negative health outcomes associated with ADHD. In this case, our results
might be biased towards finding that ADHD treatment reduces the probability of nega-
tive health outcomes. On the contrary, if, perhaps, children with the most severe ADHD
symptoms are the ones to seek treatment and are also relatively more likely to experience
negative health outcomes, the effect of medication treatment would be biased towards zero.
Second, Treatment might be correlated with α if individuals select treatment based
on expected gains. In this case, the child’s outcomes may determine treatment receipt.
2.4.2 Identification
Following Dalsgaard et al. (2014) and Duggan (2005), we instrument for individual
treatment with provider propensity to prescribe. If two equally sick patients have a different
prescription outcome because they saw physicians with a respectively high or low propen-




N patients treateddt − 1 ∗ (Treateddit = 1)
N patientsdt − 1
(2.3)
We define provider d’s propensity to prescribe (PP ) medication to an individual i in
year t as the share of all his/her patients’ treatment outcomes in a given year (Equation 2.3).
The outcome of the focal individual is excluded in order to reduce potential endogeneity
concerns since the patient’s characteristics are not a part of the provider propensity to
prescribe measure. To be included in our analysis, we require the provider to diagnose
two or more patients per year. In our data, a provider diagnoses 7 patients per year, on
average; the median is 3 patients, conditional on being included in our sample. This skewed
distribution is consistent with what is typically found in the health economics literature.
Our main estimation results are robust to only considering providers who diagnosed more
than 3 or more than 7 patients, respectively (available upon request).
Since we only observe filled prescriptions, our calculated provider’s propensity to
prescribe a drug to a patient with ADHD includes both the probability that he/she writes
a prescription and the probability that the patient fills the prescription (Dalsgaard et al.
(2014)). Both events, conditional on the provider’s engagement with the patient, are rele-
vant provider variation.21
Stockl et al. (2002) survey a 1,000 randomly selected physicians who prescribe stim-
ulant medication to patients between December 2001 and May 2002. They document con-
siderable variation in physicians’ perception of the severity of ADHD medication side effects
and their concern about the medication being used for purposes other than patient’s medi-
cal needs. Similar to earlier research, we find that patients face significant variation in the
probability of receiving a prescription (Figure 2.1).
21In the earlier literature, physician prescribing practices were found to vary with the reimbursement
mechanism (Dickstein (2014)) and their individual preferences (Hellerstein (1998)).
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Figure 2.1: Distribution of Provider Propensity to Prescribe
Notes: The figure shows the distribution of the probability that a patient receives a prescription from a particular
physician in the year she was diagnosed based on the sample of 58,685 ADHD-diagnosed patients enrolled in SC
Medicaid in 2003-2013. Provider propensity to prescribe varies from zero to one.
We, thus, use provider propensity to prescribe to instrument for the treatment
receipt. The first stage is given by Equation 2.4:
Treatmenti = δPPi +Xiθ + νi, (2.4)
where PP is a patient-specific probability to receive a prescription from the diagnosing
provider; X is a vector of controls from the Equation 2.1. The second stage is given by
Equation 2.5:
Yi = α ̂Treatmenti +Xiβ + εi, (2.5)
where ̂Treatment is the predicted treatment from Equation 2.4, and β is the marginal
treatment effects of ADHD medication on adolescent’s negative health outcomes.
To illustrate our identification strategy, consider two types of doctors: doctors with
a high propensity to prescribe and doctors with a low propensity to prescribe. For very
severe cases of ADHD, both doctors would recommend medication treatment and thus the
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effect of treatment on children’s negative health outcomes cannot be identified. Alterna-
tively, for children with few to no ADHD symptoms, both doctors would not recommend
medication treatment. The comparison of outcomes across doctors’ prescribing behaviors
would thus focus on the variation of treatment among marginal cases. Equation 2.5 will
produce consistent estimates provided that PP influences treatment and is uncorrelated
with the error term, ε (see Section 2.5 for supporting evidence). Note that we also ex-
plicitly assume monotonicity of our instrument. If a patient is prescribed medication by
a provider with a low propensity to prescribe, she must also be prescribed treatment by a
provider with a high propensity to prescribe.
2.4.3 Yearly Effects of ADHD Treatment
Another way to look at the effects of ADHD treatment on negative health outcomes
is by taking advantage of the panel feature of our data set. It allows us to control for
patient’s age, year-specific trends, and other observed time-varying factors that could have
an effect on individual health outcomes. For example, age-specific risks of outcomes such
as pregnancy, STD contraction, and substance abuse are in the fixed effects, which reduces
the variance in the error term.
Moreover, this approach requires fewer assumptions about data. While in the “life-
time” analysis (cross-section setup) it is assumed that an individual had no adverse outcomes
if she is not actively enrolled in Medicaid and has no claims,22 per-year effects are iden-
tified strictly off the observed continuous Medicaid enrollment period. Due to the nature
of administrative records, we are unable to reliably tell apart two separate negative health
events of the same type. Thus, we do not track individuals past their first adverse outcome
(except for the injuries). The empirical model is specified in the Equation 2.6 below.
Yit = α ̂Treatmenti +Xiβ+Zitγ1 +γ2Countyit +γ3Y earit +γ4Y ear×Countyit +εit, (2.6)
22See discussion in Section 2.5.2.4
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where Y is a negative health outcome for an ADHD patient i in year t; ̂Treatment represents
medical treatment instrumented with provider propensity to prescribe. As in the “lifetime”
effects analysis, treatment is defined as “treated within a year of the individual’s ADHD
diagnosis” and the instrument itself does not have a time subscript. X is a vector of
controls that includes individual characteristics that do not vary with time: race, sex,
and birth cohort; Z includes time-varying controls: age, monthly family income; Y ear
represents year controls; County stands for the county of residence;23 Y ear × County
are county/year interactions, and ε is a stochastic error term. Note that we exclude all
individuals, treated and untreated, who have experienced an adverse outcome (STD, STD
test, substance abuse, or pregnancy) prior to their ADHD diagnosis and we estimate the
model using post-ADHD diagnosis medical history. For STD, STD screening, substance
abuse, and teenage pregnancy outcomes we utilize a subsample of individuals born between
1987 and 1996, whose teen years overlap with the time period of our data set.
For the outcomes related to teenagers’ risky behavior, the parameter of interest,
α can be interpreted as the average effect of receiving treatment within a year of the
individual’s ADHD diagnosis on the first incidence of a negative health outcome. For
the incidence and number of injuries, the coefficient on treatment can be interpreted as
the average annual effect of receiving treatment within a year of the individual’s ADHD
diagnosis.
Ideally, one would like to know how treatment length or being diagnosed at a certain
age can change treatment effects. Since we are unable to address the endogeneity issues
that arise with the use of treatment length or age of diagnosis with our instrument, it is
left for the future research to find an identification strategy that would shed light on these
questions.
23For robustness, we use county unemployment rate, county income, and county population density
instead of county controls and our findings hold.
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2.5 IV Validity
2.5.1 Condition 1: First Stage Results
The first stage results for the entire sample (Table 2.3) and the outcome-specific
results (Table 2.6) show that the relationship between the provider propensity to prescribe
ADHD medication and the probability that the child fills a prescription within in a year of
their ADHD diagnosis is positive. It holds when we include a number of controls, such as
family and individual characteristics, mother’s age and education level, county, and birth
cohort fixed effects. The estimated magnitude of the coefficient in the specification that
includes all the controls and fixed effects (Table 2.3, column 3) suggests that a 10 percentage
point increase in the provider propensity to prescribe is associated with a 4.5 percentage
points increase in the probability of treatment receipt.
This relationship does not seem to be driven by the “extreme” values of provider
propensity to prescribe. When we exclude all providers who either never prescribe ADHD
medication or prescribe drugs to every child they diagnose, the first-stage result becomes
stronger.
2.5.2 Condition 2: Exclusion Restriction
In order for our instrumental variable approach to be valid, the exclusion restriction
must hold. In our data, providers are not randomly assigned to patients but it is a necessary
condition for a provider propensity to prescribe to affect patient outcomes only through
pharmacological treatment.
In this section, we devise a number of tests that could be indicative of a violation of
this assumption. There are three potential threats that we address and provide suggestive
evidence in favor of the validity of doctor propensity to prescribe. First, provider prescribing
preferences might be correlated with the provider quality and thus, would affect patient
outcomes directly rather than through treatment receipt. Second, both our instrument
and patient outcomes may be correlated with unobserved individual, family, and other
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Table 2.3: Results: First Stage
(1) (2) (3) (4)
Propensity to prescribe 0.505a 0.458a 0.454a 0.549a
(0.006) (0.006) (0.007) (0.011)
Male 0.043a 0.047a 0.047a
(0.004) (0.004) (0.005)
Race: Black -0.056a -0.055a -0.057a
(0.004) (0.005) (0.005)
Hispanic -0.126a -0.176a -0.184a
(0.011) (0.016) (0.018)
Other -0.057a -0.071a -0.077a
(0.008) (0.010) (0.011)
Family net income 0.005b 0.006c 0.005
(0.002) (0.003) (0.003)
Number of adults -0.018 0.011 -0.001
(0.003) (0.004) (0.004)
Number of children 0.001 0.001 0.002
(0.002) (0.002) (0.002)
Cohort & County F.E. N Y Y Y
Mother characteristics N N Y Y
Propensity to prescribe ∈ (0, 1) N N N Y
R-squared 0.099 0.129 0.116 0.104
N obs. 58,685 58,685 42,693 34,507
Notes: The dependent variable in every specification is the binary prescription outcome for a patient. It equals
one if the patient had an ADHD prescription within a year of their ADHD diagnosis while on Medicaid and zero
otherwise. Controls that are not shown include individual’s county of residence, foster care, and disability status
at the time of the diagnosis. Mother characteristics include mother’s age when she gave birth and educational
attainment. Family net income is measured in ten thousands of dollars; the coefficients on the number of adults
are scaled up by 10 in order to show the magnitude of the effect. Coefficient estimates that are significant at
1%, 5%, and 10% level are denoted with a, b, and c respectively. Standard errors are in parentheses. They are
clustered by individual’s provider who diagnosed them with ADHD.
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characteristics. Finally, there might be a sample selection problem if the individual’s length
of enrollment in Medicaid is related to the provider propensity to prescribe. Although these
tests do not ensure that the exclusion restriction is satisfied, they provide us with more
confidence in that our instrument is valid.
2.5.2.1 Provider quality and propensity to prescribe
Physician quality, experience, and training have an impact on patient outcomes.
If the propensity to prescribe medication reflects physician quality, it may confound our
results. For example, it could be the case that providers who prescribe medication to every
single one of their patients do not properly evaluate patient symptoms and/or determine a
treatment strategy that would suit each particular case. In other words, if high prescribing
providers are those of lower quality, we would expect to find that treatment has unfavorable
effects on health outcomes.
To address this concern we devise a placebo test. If provider quality is not related
to his or her propensity to prescribe, we should see no relationship between the instrument
and health outcomes of children who were never diagnosed with ADHD. By definition, this
group has no diagnosing physician in the data. Instead, we identify the first doctor a patient
who was never diagnosed with ADHD saw when he or she was eight years old. It is the
mean age of ADHD diagnosis in our sample of diagnosed children.24
Table 2.4 presents results for the undiagnosed sample as well as the reduced form
regression estimates for the diagnosed sample. The point estimates of the coefficients on
the propensity to prescribe have large confidence intervals suggesting that there is no sta-
tistically significant relationship between provider quality and propensity to prescribe.
2.5.2.2 Diagnosing provider selection
Another kind of potential bias may arise if parents of children with relatively severe
symptoms of ADHD seek and use prior information about the provider’s propensity to
24Due to a high provider mobility in and out of Medicaid, not all first-in-sample provider IDs were
matched to the diagnosing provider IDs.
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Panel A. Undiagnosed Children
Propensity to Prescribe 0.009 0.004 -0.003 -0.013
(0.009) (0.012) (0.008) (0.008)
Male -0.079a -0.158a 0.036a -
(0.006) (0.007) (0.006) -
Race: Black -0.031a -0.017c -0.056a -0.017b
(0.009) (0.010) (0.009) (0.008)
Hispanic -0.045a -0.038b -0.047a -0.010
(0.016) (0.019) (0.015) (0.014)
Other 0.002 -0.016 -0.071a -0.018
(0.021) (0.025) (0.017) (0.018)
Number of adults 0.0004 -0.004 -0.005 -0.008
(0.005) (0.006) (0.005) (0.005)
Number of children -0.006b -0.005 0.006b 0.013a
(0.003) (0.004) (0.003) (0.003)
Family net income 0.002 -0.007 -0.013a -0.014a
(0.004) (0.005) (0.004) (0.004)
N obs. 10,743 10,743 10,743 7,938
Panel B. Children Diagnosed with ADHD
Propensity to Prescribe -0.017c -0.037a -0.059a -0.019
(0.010) (0.012) (0.020) (0.021)
Male -0.129a -0.210a 0.048a -
(0.007) (0.008) (0.008) -
Race: Black -0.011c 0.014 -0.076a -0.023c
(0.007) (0.008) (0.010) (0.013)
Hispanic -0.037 -0.019 -0.122a -0.064c
(0.022) (0.027) (0.027) (0.037)
Other -0.023c -0.039a -0.089a -0.075a
(0.012) (0.014) (0.016) (0.024)
Number of adults -0.006c -0.019a -0.019a -0.016c
(0.004) (0.005) (0.006) (0.008)
Number of children 0.006b 0.013a 0.011a 0.034a
(0.002) (0.003) (0.003) (0.005)
Family net income -0.002 -0.008 -0.028a -0.023a
(0.004) (0.006) (0.005) (0.008)
N obs. 14,736 14,736 14,736 5,570
Notes: Panel A and B show the results of the IV validity test. Propensity to prescribe ADHD medication is
constructed using the individual’s provider at the mean age of ADHD diagnosis for the non-ADHD sample.
The coefficients in Panel A are estimated on the sample of children who do not have ADHD using OLS.
The dependent variables take value of one if a child experienced each of the respective adverse events; it
is zero otherwise. The coefficients in Panel B are from the reduced form equation: regressing the outcome
on doctor propensity to prescribe. Coefficient estimates that are significant at 1%, 5%, and 10% level are
denoted with a, b, and c respectively. Standard errors are in parentheses. They are clustered by individual’s
provider.
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prescribe. If they, on average, visit physicians with a relatively high propensity to prescribe,
this could bias our findings of the effects of ADHD medication downward. Similarly, if
the parents of children with relatively less severe ADHD symptoms seek pharmacological
treatment, it could result in an upward bias in our findings.
We do not have a strong prior on the direction of the bias. The medical evidence
on the effectiveness of ADHD medication is mixed and the evidence on long-term effects
is very limited. Additionally, there is a large array of potential side effects associated with
these drugs. They include sleep problems, suppressed appetite, nausea, headaches, stunted
growth, aggression and irritability, and cardiac risks (Barkley (2006)). Parents have to
weigh the expected benefits and costs associated with medicating their child.
Table 2.5 reports the estimates of the relationship between physician propensity
to prescribe and observed individual, mother, and family characteristics. They include
mother’s age and educational attainment at the time she gave birth, family net income
measured at the time of the individual’s first ADHD diagnosis, the severity of ADHD, and
comorbid psychiatric conditions diagnosed prior to ADHD. We find no evidence of a con-
sistent relationship between these observed characteristics and our instrumental variable
except for a tightly-estimated small in magnitude effect for the family composition, patient
gender, and race. For example, a family with one child versus two children would face a
doctor with only 0.3 percentage points lower prescribing probability. The estimates also
suggest that boys face providers who, on average, have a 1 percentage point higher propen-
sity to prescribe than girls; and Blacks are diagnosed by providers with 2 percentage points
lower propensity to prescribe than Whites. It is hard to think of a reason why conditional
on ADHD severity, provider propensity to prescribe would be correlated with patient gender
and race. In fact, when compared to the mean propensity to prescribe of 0.62, it becomes
clear that our estimates reveal precisely that: nearly zero tightly-estimated relationship.
Building on the concerns identified in the earlier literature (Dalsgaard et al. (2014),
Currie et al. (2014)) we look at the relationship between provider propensity to prescribe
and patient family socio-economic status. We find a very small and statistically insignifi-
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cant correlation between family income and provider propensity to prescribe. An increase
of $400 in monthly family income (median income in our sample) would imply a 0.8 per-
centage points lower provider propensity to prescribe. Medicaid enrollees are a relatively
homogeneous group income-wise and are well-suited for our research design. Finally, we
find no statistically significant relationship between provider propensity to prescribe and
the severity of the underlying condition approximated by the history of injuries prior to the
ADHD diagnosis.
Although there are many unobserved characteristics that could have an impact on
the choice of the ADHD provider, we argue that our test has significant power. Covariates
like family income and mother’s characteristics have a long history of being used as predic-
tors of health, parent quality, and other outcomes that we could be potentially concerned
about.
2.5.2.3 Treatment shopping
About 10% patients in our sample (5,734 individuals) switch their health care
provider after being diagnosed with ADHD. If the reason behind a switch is a patient’s
desire to alter their treatment, it could undermine our research design. In particular, the
concern is that patients are shopping for treatment and if the first physician did not pre-
scribe medication, they would search for a provider who would. For these patients, we
look at the relationship between prescribing practices of the diagnosing physician and their
subsequent physician. Of the individuals that switch providers, 57.6% go to a subsequent
provider with a higher propensity to prescribe than the diagnosing provider; 39.4% go to
a subsequent provider with a lower propensity to prescribe, and 3.0% go to a subsequent
provider with a propensity to prescribe equal to the first diagnosing provider. Approxi-
mately 83% of switchers receive pharmaceutical treatment and 79% of those who do not
switch receive pharmaceutical treatment.
Figure 2.2 plots this relationship. It shows no clear linear pattern in the switchers’
behavior, suggesting that individuals who switch to a subsequent provider do so randomly
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or for reasons independent of the provider propensity to prescribe. We also look for the pos-
sibility of a nonlinear relationship. The coefficient on the quadratic term is small, positive
and significant (0.07 (0.01)).25 It suggests that for patients who first encounter providers
with “extreme” prescribing preferences (either prescribe to no one or prescribe to all pa-
tients) and switch to another provider, their subsequent provider propensity to prescribe is
slightly higher than average. If we regress the individual decision to switch on an indicator
of provider being “extreme”, we find that their patients are 2 percentage points more likely
to switch providers (Table 19).
Further, we find no evidence of correlation between provider switching and mother’s
education or income (Table 19), and the mean values of mother and family characteristics do
not differ significantly for individuals who go to a higher prescribing subsequent provider in
relationship to individuals who go to a lower prescribing subsequent provider (Table 20). All
these patterns suggest that strategic treatment shopping in our sample is not a significant
issue but it also indicates that patients might be driven away from providers with the
extreme preferences to prescribe ADHD medication.
2.5.2.4 Provider propensity to prescribe and the length of Medicaid enrollment
The final test we perform is concerned with the length an individual is enrolled in
Medicaid. In the data, we observe the individual so long as they are enrolled. If the decision
to enroll in Medicaid is related to doctor propensity to prescribe, it is a potential concern
for the identification strategy.
For example, if a patient was diagnosed by a provider with a relatively high propen-
sity to prescribe and received medication, it is plausible to suggest that she may remain
enrolled for a longer period of time than otherwise. One might argue that the longer an
individual is enrolled, the more probable it is that we will observe a negative health outcome
for that individual: STD contraction, STD screening, substance abuse disorder, or teenage
25The coefficient estimates do not change when controls from our main regression specification are in-
cluded.
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Figure 2.2: Provider Shopping: Diagnosing and Subsequent Provider Propensity to Pre-
scribe
Notes: In the data, 5,734 patients switch health care providers. This figure shows the relationship between the
individual’s diagnosing provider propensity to prescribe and their subsequent provider propensity to prescribe. Pre-
scribing propensities vary from zero to one.The bubble size indicates the number of patients for each pair of propensity
scores.
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pregnancy.26 Positive correlation between doctor propensity to prescribe and enrollment
could bias our results towards finding that pharmaceutical treatment receipt, instrumented
with provider propensity to prescribe, is correlated with worse patient outcomes.
Table 2.5 shows that the instrument is uncorrelated with the length of Medicaid
enrollment. In other words, individuals are not selecting into the sample based on their
diagnosing provider propensity to prescribe.
Table 2.5: IV Validity: Additional Evidence
Dependent Variable: Propensityto Prescribe
Enrollment
Length
Regressors Coeff. SE Coeff. SE
Individual Characteristics
Male 0.011a 0.003 -0.081a 0.016
Race: Black -0.020a 0.003 0.292a 0.017
Hispanic -0.049a 0.009 0.171a 0.057
Other -0.035a 0.005 0.187a 0.036
Mother & Family Characteristics
Educ: Less than HS 0.002 0.006 0.103b 0.039
Some HS -0.002 0.003 0.077a 0.018
Some college -0.004 0.004 -0.269a 0.024
College degree or higher 0.003 0.006 -0.406a 0.036
Family net income -0.002 0.002 -0.083a 0.010
Number of adults 0.004b 0.002 0.051a 0.013
Number of children 0.003b 0.001 0.059a 0.007
Comorbid condition -0.002 0.003 0.135a 0.016
Severity of ADHD -0.001 0.003
Provider Propensity to Prescribe 0.006 0.028
N obs. 39,753 42,140
Notes: This table shows two additional tests in support of our instrumental variable. Both regressions
are estimated using OLS and include birth cohort and county fixed effects. Family income is measured
in thousands of dollars; ADHD severity is approximated by the incidence of injuries prior to ADHD
diagnosis. Family characteristics are measured and fixed at the time of the individual’s first ADHD
diagnosis. Coefficient estimates that are significant at 1%, 5%, and 10% level are denoted with a, b, and
c respectively.
26Due to the easiness of enrollment in Medicaid and including the fact that the program would cover up to
two months of claims retroactively, these adverse outcomes would likely result in an individual re-enrollment
and would not pose a risk for the model identification.
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2.6 Results
We find evidence that ADHD medication treatment reduces the probability and
severity of a wide range of short-term and lifetime negative health outcomes. It is effective
in reducing the probability of an ADHD teenager contracting an STD, becoming pregnant,
suffering from a substance use and abuse disorder, and having an injury.
Tables 2.6–2.9 summarize these results. For every negative health outcome we show
coefficients estimated using IV and OLS, for comparison purposes. OLS estimates agree
with the IV-estimated coefficients in the direction of the effect, but in most cases they
understate the magnitude of the beneficial effects associated with treatment.
2.6.1 Lifetime Effects of ADHD Treatment
We first look at the effect of treatment on the incidence of negative health events
over the childhood and teenage years. Table 2.6 summarizes the results. We find that med-
ication is effective in reducing the probability of the outcomes produced by risky behaviors.
Children with ADHD, who received pharmacological treatment are 3.6 percentage points
less likely to be treated for an STD condition, 5.8 percentage points less likely to be screened
for an STD/have a condition, and 7.3 percentage points less likely to receive medical atten-
tion related to a substance abuse disorder. The point estimate on the probability of teenage
pregnancy is also negative (-2.3 percentage points) but not statistically significant.27
Compared to the OLS estimates, the coefficients obtained using IV are of the same
sign for all outcomes, but are larger in absolute value and statistically significant for STD
contraction, STD screening and substance abuse disorder. In other words, OLS understates
the effects of treatment but indicates that treatment has favorable effects on outcomes.
The results also show that males are less likely to be treated (12.0 percentage points)
or screened (20.5 percentage points) for an STD but 4.1 percentage points more likely to
have medical history of substance abuse. This finding is consistent with the reports on
27These results generally hold in a smaller sample of patients for whom we have birth certificate data.
Table 21 shows the effects of ADHD treatment on negative outcomes when we control for mother’s age and
educational attainment.
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STDs.28 For example, the chlamydia case rate per 100,000 females in 2005 was more than
three times higher than for males. Most of this difference is attributed to the fact that
women are more likely to be screened than men. Whites are the most likely to suffer from
one of the negative health outcomes that we focus on, which is also likely to be an outcome
of higher probability of being screened.
Family characteristics that we control for include family composition (number of
adults and children in the individual’s household) as well as family net income at the time
of the child’s diagnosis. The coefficients on these controls are consistent with our prior.
In a family with a single adult comparing to a family with two adults, the probability
of negative health outcomes is 0.6-1.6 percentage points lower depending on the type of
the outcome. This result is statistically significant for the STD condition and screening
combined, substance abuse, and teen pregnancy.
On the other hand, individuals in families with a higher number of children are more
likely to experience one of the negative health outcomes. The magnitude of the effect varies
from 0.6 to 3.4 percentage points, being the highest for teenage pregnancy. It is likely
due to the fact that there is relatively less parental oversight in larger families. Finally,
net family income is negatively correlated with the incidence of risky behavior outcomes.
As we would expect, the better off the family is in terms of income, the less likely their
child will experience a negative health outcome, however the magnitude of the effect is very
low. A $100 increase in the net monthly income would produce a 0.02, 0.08, 0.27, and
0.23 percentage point decrease in the probability of STD, STD screening, substance abuse,
and teen pregnancy respectively. Note that most families on Medicaid are relatively poor
and there is not enough income variation in this population group to evaluate the effect of
income on the incidence of negative health outcomes.
Table 22 in the Appendix shows that the results are robust to including a control
for comorbid psychiatric conditions that an individual is diagnosed with prior to their
ADHD diagnosis. When we exclude individuals who have been diagnosed with a comorbid
28CDC, “Trends in Reportable Sexually Transmitted Diseases in the United States, 2005”,
http://www.cdc.gov/std/stats05/trends2005.htm. Accessed on July 14, 2015.
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psychiatric condition prior to their ADHD diagnosis, our results hold for all the outcomes.
We also explore how our results vary across ADHD-diagnosed patients of different
gender, race, and birth cohort. The results are reported in Table 2.7. These stratifications
provide us with interesting insights. The results for male and female subpopulations suggest
that treatment reduces the probability of STD contraction and STD screening for both
males and females but estimates are statistically significant only for females. As previously
discussed, females have a higher prevalence of STDs likely due to the fact that they are
screened for STDs more often than males. Treatment also reduces the probability of abusing
substances for both males and females but the effect is only statistically significant for males.
For most outcomes we find little heterogeneity across races. Treatment reduces
the probability of STD contraction, STD testing and substance abuse for both Whites
and minorities; however the point estimates are imprecise for Whites. Finally, treatment is
associated with a statistically insignificant reduction in the probability of teenage pregnancy
for Whites; for minorities the point estimate is nearly zero and imprecise.
Following earlier research, we split patients by the year of birth into two groups:
relatively “older” and “younger” cohorts. Our results are consistent with Dalsgaard et al.
(2014), who find treatment to be less effective in younger cohorts. We interpret this result
in light of increased incidence of ADHD diagnosis. It is suggestive of the average ADHD
case being less severe in relatively younger cohorts than in older cohorts.
2.6.2 Yearly Effects of ADHD Treatment
Perhaps an even more policy-relevant question is what is the difference in outcomes
for children who are treated with ADHD medication versus children who are not in per
year terms. The average cost of a prescription medication is $347 per patient per year
and the average cost of ADHD-related physician visits is $562 per patient per year during
the sample period (measured in 2013 dollars). It is valuable to compare these treatment
expenditures to what Medicaid spends on treatment of realized negative health outcomes.29
29It is one of the goals of our future work to differentiate these effects by the year of diagnosis, adherence




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Panel A. Gender-based heterogeneity
Male -0.007 -0.035 -0.096b –
(0.020) (0.026) (0.042)
Mean 0.067 0.127 0.239 –
N 8,985 8,887 8,502
Female -0.089a -0.117a -0.047 –
(0.032) (0.039) (0.045)
Mean 0.203 0.364 0.231 –
N 5,263 5,009 5,166
Panel B. Race-based heterogeneity
White -0.032 -0.042 -0.072 -0.079
(0.036) (0.040) (0.053) (0.063)
Mean 0.122 0.199 0.266 0.280
N 6,410 6,256 6,179 2,648
Minorities -0.043b -0.068b -0.084b 0.018
(0.021) (0.027) (0.042) (0.044)
Mean 0.115 0.225 0.216 0.255
N 7,640 7,450 7,297 2,615
Panel C. Cohort-based heterogeneity
Old -0.047 -0.093b -0.154b -0.130c
(0.033) (0.040) (0.064) (0.076)
Mean 0.120 0.194 0.247 0.373
N 3,692 3,552 3,404 1,359
Young -0.027 -0.040 -0.039 0.021
(0.022) (0.027) (0.035) (0.041)
Mean 0.116 0.219 0.232 0.228
N 10,556 10,344 10,264 3,980
Notes: This table reports the coefficient on ADHD treatment from the Equation 5 esti-
mated on three subpopulations, stratified by gender, race, and birth cohort. Coefficient
estimates that are significant at 1%, 5%, and 10% level are denoted with a, b, and c
respectively. Standard errors are in parentheses.
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The results suggest that pharmaceutical treatment is associated with a 1.1 percent-
age point decrease in the probability of contracting an STD, a 1.9 percentage point decrease
in the probability of being screened for an STD, a 1.8 percentage point decrease in the prob-
ability of abusing substances, and a 2.3 percentage point decrease in the probability of being
injured, or a reduction of 0.081 injuries in a given year. Our findings for injuries are in line
with the findings of Dalsgaard et al. (2014).
The panel analysis results reported in Table 2.8 are consistent with our cross-section
analysis: we find that treatment is associated with a reduction in the probability of con-
tracting an STD, being screened for an STD, and abusing substances. The magnitudes
of the coefficients in the yearly effects regressions are complementary rather than directly
comparable to the lifetime effects of ADHD treatment. In the former we specifically focus
on the periods of the child’s continuous enrollment in Medicaid, controlling for the patient’s
age and other time-varying parameters.
The coefficients on covariates of interest also support the earlier reported results on
the lifetime effects of treatment. For the probability of injuries, the signs are as expected.
Boys are 2.8 percentage points more likely than girls to have an injury in a given year.
Whites are more likely to suffer from most negative health outcomes, including injuries,
than Blacks and Hispanics. We posit that this is related to the likelihood of using medical
services in general, as discussed earlier.
2.6.3 Effects of ADHD Treatment on Medicaid Spending
Only occasionally ICD-9 diagnosis codes and CPT procedure codes that we used
to identify the incidence of negative health outcomes, are indicative of severity of the un-
derlying condition. It is plausible, however, that ADHD medication has an effect not only
on the incidence of the negative health events but also on their severity. A way to address
this question is to look at the direct cost to Medicaid of the outcomes that we observe in
the data (with an exception of pregnancy). We posit that the more visits are needed and




















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































an adverse event, we use Medicaid payments to the providers to calculate the cost of this
outcome. The cost is zero if a patient did not experienced a negative health outcome.30
Panel A of Table 2.9 shows the results for the average annual cost to Medicaid
over the patients’ lifetime enrollment period for STD, STD screening, substance abuse, and
injuries. In Panel B, we look at the data in per year terms and control for patient age
and other time-varying characteristics. If a patient is treated for ADHD, every patient per
year would cost Medicaid $10.34 ($20.64) less in STD-related expenses (if we include STD
tests); $93.68 less in substance abuse-related costs, and $88.37 fewer in injury spending.
In relative terms, treatment reduces spending on substance abuse disorders by 0.061 of a
standard deviation and injury spending by 0.054 of a standard deviation.
Note that both lifetime and per year effects of treatment on the incidence of STD
and STD combined with screening are large and negative, but the effects on costs related to
these events are rather modest. This is likely due to the difficulty of measuring STD-related
costs. Our STD cost measure only includes expenses related to provider visits. The most
billing procedure codes that go along with an STD diagnosis are one-time screening and the
visit itself. By construction, STD spending will have no-charge periods with intermittent
chargers for STD test and office visit in the absence of pharmacological treatment spending
information. Thus, our STD spending measure is understating the effect.
For one of our outcomes, substance abuse, we were able to take advantage of the
earlier literature to construct a comprehensive cost measure that includes medical doctor
visits and the cost of pharmacological treatment. We are not aware of methodological work
that would help us construct the same measure for STDs. This might explain the fact that
the results on the incidence and cost of substance abuse are better aligned than the results
for STD.
OLS estimates that we present for comparison purposes, have the same sign as the
IV estimates, but are mostly noisy.



































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































We perform several robustness checks. First, we test the sensitivity of the results to
alternative definitions of pharmacological treatment. Our findings have the same signs on
the coefficients of interest and differ from the baseline specification results in an expected
way. Second, we introduce two alternative instrumental variables: the first-in-data provider
propensity to prescribe and a geographic instrument based on child’s school location. The
alternative IVs would be expected to have weaker explanatory power but they are arguably
more exogenous. Both instruments provide evidence compatible with our preferred instru-
ment. The summary of the results is shown in Table 2.10. Each row represents the three
different treatment definitions; and reports both the first stage coefficient and the coeffi-
cient on treatment instrumented with an alternative IV and our preferred instrument for
comparison purposes.
2.7.1 Alternative definition of treatment
Pharmacological treatment can be defined in a number of ways. Our baseline def-
inition considers an individual as treated if they have a record of taking any medication
approved for ADHD within a year of their ADHD diagnosis. Alternatively, we could assign
the treated status to individuals who ever take a prescription after their ADHD diagnosis.
Whereas our baseline definition of treatment assumes that the instrument only has an effect
on treatment receipt within a year of the individual’s ADHD diagnosis (and has no effect on
outside treatment channels), this definition of treatment requires a less strict assumption
of the exclusion restriction. The relationship between the provider propensity to prescribe
medication and treatment under this definition is weaker, as expected (Table 2.10). The
estimation yields relatively larger point estimates for treatment in absolute value compared
to our baseline specification. This result might be explained by the fact that 7% patients re-
ceive treatment later than a year since the initial diagnosis and did not experience negative
outcomes, but are being coded as never treated in our baseline specification.
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For the second test, we follow earlier literature (see Dalsgaard et al. (2014)) and
assign treatment status to the individuals who were treated for at least 6 months in a given
year. This definition captures the idea of treatment adherence. Indeed, one prescription
would not cure or even alleviate the condition, but half a year of treatment is more likely
to have an impact on the child’s health and behavioral outcomes. Again, by construction,
the relationship between the provider propensity to prescribe medication and treatment
adherence of six months or more is weaker (Table 2.10). Perhaps not surprising, when we
define the treated population as only those who adhere to treatment for six months, we find
treatment to be more effective.
We present these results for comparison purposes and we argue that our baseline
treatment accounts for the timing of treatment and occurrence of negative health events.
Under the definition of “ever treated”, we can not exclude the possibility that some individ-
uals would be first diagnosed with ADHD, then experience an adverse outcome, and only
then receive treatment. The other alternative treatment definition, “filling 6 prescriptions
or more in a given year”, is hard to defend against the argument that the provider might
influence adherence to treatment and health outcomes through channels other than the act
of simply prescribing medication. In other words, our IV estimates can be interpreted as a
lower bound on the effects of treatment on negative health outcomes.
2.7.2 Alternative instrumental variables
We construct two alternative instrumental variables and test them on the treatment
definitions described above. First, we calculate provider propensity to prescribe index for
the the first-in-data provider rather than the diagnosing provider. The purpose behind this
IV is to address potential concerns about the provider selection based on the probability
they would prescribe medication. We argue that children visit their pediatrician or family
physician routinely, for most health issues, including ADHD, rather than selecting a specific
provider to go to with ADHD-related concerns. We calculate a measure of prescribing
preferences for the first-in-data provider based on all patients with ADHD the provider
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diagnosed in that year. Note that not all providers have patients with ADHD every year
and there is also a significant provider mobility in and out of Medicaid. For this reason, we
do not have a first-in-data provider propensity to prescribe for everyone who was diagnosed
with ADHD in our sample.
In line with our main specification findings, the results utilizing the first-in-data
provider preferences suggest that treatment reduces the probability of STD contraction,
STD screening, and substance abuse disorders (Table 2.10). A smaller sample size likely
explains the increase in the noisiness of our coefficient estimates. These results provide
additional support to the evidence we presented on the absence of provider selection (Sec-
tion 2.5).
Next, we define a geographic area-based alternative instrument. It is constructed
using the school a patient is attending. We take the fraction of other students treated
with medication divided by the total number of students diagnosed with ADHD in the
individual’s year of diagnosis at the school. The results suggest that treatment reduces
the probability of STD contraction, STD screening, and abusing substances, however the
estimates are noisy likely due to the relatively weaker first stage. The first stage estimates
are statistically weak for treatment defined as treated for at least 6 months in a given year












































































































































































































































































































































































































































































































































































































































































































































































































































































This paper investigates the effectiveness of ADHD medication in reducing the prob-
ability of short-term and long-term negative health outcomes associated with the disorder.
Over the past decade, SC Medicaid spending on prescription drugs increased nearly three-
fold to $69 million in 2013. It is important to understand whether the increased expenditures
on treatment produced any benefit in terms of improved health (fewer and less severe in-
juries), reduction in risky behaviors that potentially lead to teen pregnancies, STDs, and
substance use and abuse. The focus population of our study are children from relatively
disadvantaged families who are enrolled in SC Medicaid and who are diagnosed with ADHD.
This population is particularly vulnerable: up to a quarter of Medicaid enrollees are diag-
nosed with ADHD in their birth cohort. Although we are unable to make a statement on
the effectiveness of ADHD treatment in general population, our sample represents a large
fraction of the state population, and an even larger fraction of diagnosed children. Since
children on Medicaid are disproportionately diagnosed with ADHD and their incentives are
distorted in the absence of a drug price tag, this population should be of primary focus.
Our panel data set includes all SC Medicaid claims between 2003 and 2013. To
overcome potential endogeneity of treatment take-up, we use variation in physician pre-
scribing preferences for ADHD. Our findings suggest that ADHD medication is effective in
reducing the probability of the negative health and behavioral outcomes that we are able
to identify in administrative data. Based on our preferred specification, over the course of
teenage years the probability of contracting an STD decreases by 3.6 percentage points; an
individual is 5.8 percentage points less likely to be screened for an STD/have a condition;
and 7.3 percentage points less likely to receive medical attention related to a substance
abuse disorder if treated with ADHD medication. The point estimate on the probability of
teenage pregnancy is also negative (-2.3 percentage points) but not statistically significant.
Controlling for time-varying characteristics, these findings translate into a 1.1 per-
centage point decrease in the probability of contracting an STD, a 1.9 percentage point
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decrease in the probability of being screened for an STD, a 1.8 percentage point decrease in
the probability of abusing substances, and a 2.3 percentage point decrease in the probability
of being injured, or 0.081 reduction in the number of injury-related medical procedures in
a given year.
These results generally agree with the findings of Dalsgaard et al. (2014), who find
that medication is effective in reducing the number of hospital contacts and the likelihood
of criminal activity. However, Currie et al. (2014) find that an increase in medication
use is associated with negative effects on children’s educational outcomes, deterioration in
relationships with parents, and increase in the probability of depression. These differences
are suggestive of ADHD medication having varying effects on noncognitive human capital
in comparison to cognitive abilities.
It is plausible to suggest that ADHD medication has an effect not only on the
incidence of negative health outcomes but also on their severity. We go beyond the existing
literature and address this question by looking at the direct cost to Medicaid of all outcomes
that we observe in the data (except for pregnancy). We posit that the more visits are needed
and the costlier they are, the more severe is the patient’s condition. For every patient treated
for ADHD, each year of eligibility would cost Medicaid an estimated $10.34 ($20.64) less
in STD-related expenses (if we include STD tests); $93.68 less in substance abuse-related
costs and $88.37 in injury spending. In per year terms, when we control for patient age
and other time-varying characteristics, the results tell the same story and are very similar
in magnitude.
The limitations of this study that we hope to address in future research include the
scope of the effects of interest and external validity. First, our results reflect the effect of
treatment of a marginal patient and do not attempt to measure the benefit of pharmaceutical
treatment for children with ADHD that will inevitably be treated. Second, although our
sample of Medicaid children makes up a large proportion of the population diagnosed with
ADHD, the results are not necessarily generalizable to the non-Medicaid population. At the
same time, the population in our study is the most affected by the negative health outcomes
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that children with ADHD are prone to, which makes our findings even more policy-relevant.
On average, SC Medicaid spent $347 for prescription medication and $562 on
ADHD-related physician visits, including behavioral therapy, while the total savings across
all negative health outcomes summed up to $221 on average per child per year. However,
these “savings” do not include the costs associated with teenage pregnancies, any indirect
benefits that stem from preventing negative health and behavioral outcomes, or any indi-
rect benefits that accrue to the patients’ peers. We are also not able to estimate costs of
side effects of the medication. With the increasing rates of ADHD diagnosis and respective
government spending on programs like Medicaid as well as Medicaid expansion, comparison
of treatment costs and benefits deserve special investigation in future work.
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Chapter 3
Social Security Supplemental Security Income
(SSI) Disability Benefits on Future Educational
Achievement (with Timothy Bersak)
3.1 Introduction
Lower birth weight infants have worse health and academic outcomes. The detri-
ments of low birth weight persist in the long-run and adversely affect adult schooling at-
tainment and earnings (Behrman and Rosenzweig (2004), Black et al. (2007), Fletcher
(2011)). The federal Supplemental Security Income (SSI) program provides cash transfers
to individuals with low incomes and resources who are aged, disabled, or blind, including
disabled children. There is no minimum age requirement necessary to establish a medically
determinable impairment, and in practice some infants are found to be disabled and eligi-
ble for the SSI program from birth. Of particular note, under Disability Insurance listing
34005.100, low birth weight and failure to thrive, infants can be found eligible for SSI if
they are born at a low weight relative to their gestational age, regardless of whether there
are any additional impairments present. Because the exact weight thresholds are somewhat
arbitrary this feature of the program provides an effectively random determinant of benefit
receipt. Infants, that are otherwise observationally similar, differ in their eligibility for and
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receipt of benefits solely based upon which side of the threshold their birth weight happens
to fall. As low birth weight is not the only criteria through which a child can establish
a medically determinable impairment, there will be some infants who are born above the
threshold that also qualify for SSI payments. The full list of thresholds is contained in the
table below.
Table 3.1: Eligibility of SSI Receipt Weight and Gestational Age Thresholds
Gestational Age Birth weight Birth weight
(weeks) (grams) (lbs & oz)
>=37-40 <=2000 4lbs & 6.50oz
>=36 <=1875 4lbs & 2.14oz
>=35 <=1700 3lbs & 11.97oz
>=34 <=1500 3lbs & 4.91oz
>=33 <=1325 2lbs & 14.74oz
>=32 <=1250 2lbs & 12.09oz
ANY <1200 2lbs & 10.33oz
Source: SSA Program Operations Manual System
If an infant is eligible for SSI, the 2017 maximum federal benefit amount is 735
dollars per month, though this figure can be reduced depending on how much family income
is deemed available to support the child. Typically, when infants are found eligible for SSI,
their case will be reviewed after a period of two years to determine if the child continues to
be eligible for the program. Absent any frictions, this means that the impact of birth weight
relative to an eligibility threshold on benefit receipt should entirely disappear after the first
two years of life, though in practice there is probably some persistence of benefit eligibility,
meaning that future rates of disability receipt are likely to converge but not entirely equalize
as a child ages.
This paper contributes to several important strands of literature. A large body of
work has looked at the impacts of income and cash transfer programs on early childhood and
educational outcomes. In a working paper, Guldi et al. (2017) exploit the discontinuity of
the lowest birth weight threshold for SSI eligibility to estimate the impacts of supplemental
security income on early childhood outcomes. Hoyne et al. (2016) exploit the sequential
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rollout of the Food Stamp program and find that increasing a family’s economic resources
during early childhood leads to improved health outcomes and an increase in economic self
sufficiency later in life. Akee et al. (2010) find that unconditional cash transfer payments
from casino profits increase educational attainment before the age of 21 for children in the
poorest households. Their study also suggests that improved parental quality is the likely
mechanism that drives improved outcomes. Maurin (2002) estimates that a 10 percent
increase in family incomes is associated with a 6.5 percent decrease in the probability of
repeating a grade during elementary school for children in France, suggesting potentially
large impacts of social programs that provide cash transfers to low income families. Berger
et al. (2009) estimate that higher incomes in early childhood are associated with better
cognitive and behavioral outcomes at age 3, and their estimates are consistent with the
hypothesis that the mechanism through which income improves outcomes is better parenting
and home environments. Shea (2000) employs an instrumental variable strategy using
variations in income that are arguably due to luck and estimates that parental income has
a negligible impact on both the future earnings and educational achievement of children,
although Shea finds some evidence that increased income improves outcomes for the children
of parents with low levels of educations.
A secondary contribution of this paper is to the literature that investigates the
relationship between low birth weight and future health and economic outcomes.
3.2 Data and Descriptive Statistics
We merge South Carolina birth certificate data with data on student academic
records over the years 2003 to 2013. The academic performance measures are utilized for
individuals in kindergarten through eighth grade.
The birth certificate data include vital statistics variables collected at the time of
the child’s birth: birth weight, gestational age, mother’s age at birth, mother’s education
at birth, a measure of tobacco use medical risk, and the number of prenatal care visits. The
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Department of Education data include measures of student performance: grade repetition,
whether the individual has a registered learning disability, and elementary and middle school
test scores (South Carolina Palmetto Assessment of State Standards), 1 To be included in
our analysis, we require the infant to be within 200 grams of the birth weight thresholds.2
Table 3.2 reports summary statistics for the academic outcome measures we consider in
our analysis. We define grade repetition equal to 1 if the individual ever repeats a grade
in elementary or middle school, and zero if not. Learning disabilities are recorded by the
individual’s school likely for special educational purposes. Finally, the test score outcomes
are the average of the individual’s English and mathematics standardized test scores by
grade.
Using the individual’s gestational age and birth weight, we determine if the individ-
ual is eligible for SSI disability benefits at birth using Table 3.1. In our main analysis, we
include infants at all SSI birth weight eligibility cutoffs. For robustness, we exclude infants
in the 1500 gram birth weight (<=34 gestational weeks) threshold as these individuals could
also be treated by medical interventions (Almond et al., 2010). Table 3.3 reports the mean
values for outcome measures and covariates by each birth weight threshold.
Table 3.2: Outcome Summary Statistics
N obs. Mean Std. Dev. Min Max
Academic Outcome Measures
Grade repetition 2384 0.180 0.384 0 1
Learning disability 2384 0.208 0.406 0 1
Average Mathematics & English Test Scores
3rd grade 691 2.920 1.123 1 5
4th grade 751 2.728 0.991 1 5
5th grade 821 2.679 0.995 1 5
6th grade 840 2.598 1.044 1 5
7th grade 836 2.525 1.027 1 5
8th grade 824 2.419 0.998 1 5
Notes: The sample includes all observations within 200 grams of all birth weight thresholds.
1South Carolina Palmetto Assessment State Standards includes testing in subjects of English, math,
science, social studies, and writing.
2For robustness, we also make use of a 150 gram bandwidth.
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Table 3.3: Summary Statistics: Mean Values for Outcomes & Covariates by Threshold
Threshold
<1200g <=1250g <=1325g <=1500g <=1700g ¡=1875g <=2000g
Covariates
Mother’s age 24.036 24.624 25.117 24.9134 24.450 24.647 24.362
Mother’s education 11.532 10.882 11.447 11.835 11.167 11.753 11.427
Tobacco risk measure 1.870 1.849 1.894 1.795 1.844 1.760 1.752
Male 0.467 0.473 0.489 0.354 0.402 0.339 0.326
# prenatal visits 7.317 8.830 9.303 9.276 10.949 10.437 10.777
Academic Outcome Measures
Grade repetition 0.177 0.151 0.160 0.197 0.156 0.201 0.182
Learning disability 0.267 0.258 0.170 0.213 0.167 0.163 0.173
Notes: The sample includes all observations within 200 grams of all birth weight thresholds.
3.3 Empirical Strategy
Infants can be found eligible for SSI disability payments if they are born at a low
weight relative to their gestational age. Due to these somewhat arbitrary weight thresholds,
in our analysis we compare infants, that are otherwise observationally similar but differ in
their eligibility for and receipt of benefits. Because low birth weight is not the only criteria
through which a child can receive SSI disability payments, and because we are unable to
observe if an infant actually receives SSI disability payments, we utilize a fuzzy regression
discontinuity (RD) design to estimate the effects of SSI eligibility for infants on future aca-
demic outcomes.
Because our analysis makes use of multiple thresholds determined by both gesta-
tional age and birth weight (see Table 3.1), we estimate the following equation:











where Yi represents the academic outcome we investigate for individual i : grade
repetition and reported learning disability. The indicator variables Ddi take a value of 1 if
the individual is categorized within that threshold determined by their gestational age and
birth weight, righti is an indicator variable for whether the individual’s birth weight lies to
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the right of its relevant threshold (and are thus not eligible for SSI disability payments), and
fd(birthweighti) is a polynomial in birth weight difference from the threshold. Because SSI
disability is determined by both gestational age and birth weight, each infant by definition
falls within only one threshold. We use bandwidth choices of 200 grams and 150 grams
(Guldi et. al). The parameter β is our parameter of interest and estimates the local
average treatment effect of not being eligible for SSI disability payments.
3.4 Validity of RDD
3.4.1 Frequency of Births Around Weight Thresholds
In order for regression discontinuity design to be valid, birth weight must not be
precisely controlled. The validity of our design would be threatened if reported birth weight
is strategically reported. In Figure 3.1 we investigate this possibility by plotting the number
of births by birth weight. Because we make use of multiple birth weight thresholds, Figure
3.1 plots each individuals’ birth weight by subtracting off the relevant birth weight cutoff
threshold. The x-axis therefore is measured as the distance from the relevant weight cutoff
thresholds and centers each birth weight threshold at 0. The first histogram plots birth
weights for the entire sample of individuals for whom we observe a birth weight. Much of
our analysis will focus on birth weight within 200 grams of the weight threshold cutoff. The
second histogram zooms in on the relevant range of birthweights within 300 grams of the
threshold cutoff.
Neither histogram shows evidence of strategic reporting of birth weight just below the
thresholds. However, as expected due to physician rounding of birth weight, there is sub-
stantial heaping of births at round number of ounces (Barreca et al., 2011).
87
3.4.2 Comparison of Covariates
It would be problematic for our empirical strategy if we observed discontinuities in
the baseline covariates such as mother’s age at birth, mother’s education at birth, tobacco
use, and number of prenatal visits. If this were the case, it could imply that our results
are driven by these covariate differentials instead of SSI disability eligibility. We test for
discontinuities in the baseline covariates at the thresholds by plotting these covariates to
the left and right of the birth weight thresholds, and by replacing each of the covariates
as the dependent variable in our main specification. Table 3.4 reports the RD parameter
estimates and Figure 3.2 displays the RD plots. We find no evidence of a discontinuity in
our baseline covariates suggesting that infants born just below the SSI disability eligibility
threshold are suitable comparisons for infants born just above the SSI disability eligibility
threshold. To assure our results capture solely the effects of SSI disability eligibility and
not other potential medical interventions, we exclude infants surrounding the 1500 gram
birth weight (<=34 gestational weeks) threshold (Almond et al., 2010).
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Table 3.4: Balance Check on Baseline Covariates
SSI Eligibility
200g window 150g window
Dependent Variables
Mother’s age -0.319 -0.773
(0.509) (0.605)
2,384 1,676









# Prenatal Visits 0.100 0.301
(0.422) (0.510)
2,291 1,607
Notes: The coefficient estimates in this table represent the effect of being
ineligible for SSI disability payments on baseline covariates. Coefficient es-
timates that are significant at 1%, 5%, and 10% level are denoted with ***,
**, and * respectively. Standard errors are in parentheses. The number of
observations is reported beneath the standard errors.
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Figure 3.1: Birth Weight Thresholds
Notes: The figures plot the frequency of births by birth weight. The x-axis represents the distance
from the weight cutoff thresholds.
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(e) number of prenatal visits
Notes: The figures plot average values for each covariate within the bins to the left and right of
the birth weight thresholds.
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3.5 Results
We first examine the effects of SSI disability eligibility on the probability of repeating
a grade elementary or middle school and the probability that the individual has a registered
learning disability in their school. Approximately 18% of the sample we investigate repeats
at least one grade within elementary through middle school and nearly 20% of the sample has
a registered learning disability in their school. Table 3.5 reports the RD parameter estimates
on grade repetition and learning disabilities for 200 gram and 150 gram bandwidths. For
each outcome, the first row presents results from the linear flexible models and the second
row presents results from the quadratic flexible model.
The first column shows that infants who are eligible for SSI disability benefits are
4.5 - 7 percentage points less likely to ever repeat a grade in elementary or middle school.
When we narrow the bandwidth to 150 grams around the thresholds, the estimates still
suggest that infants eligible for SSI disability benefits are 4.4 - 6.1 percentage points less
likely to ever repeat a grade but the estimate is no longer statistically significant, likely
due to the sample size reduction. The second column shows that infants who are eligible
for SSI disability benefits are 7.2 - 7.6 percentage points more likely to have a registered
learning disability in their school. When we narrow the bandwidth to 150 grams around the
thresholds, we still find a statistically significant effect that SSI disability eligibility increases
the likelihood of registering a learning disability in school by 6.7 percentage points.
92
Table 3.5: SSI Disability Eligibility Effects on Outcomes
Grade Repetition Learning Disability
200g window 150g window 200g window 150g window
Flexible Linear
SSI Eligibility 0.070** 0.061 -0.076** -0.067*
(0.032) (0.038) (0.034) (0.040)
Flexible Quadratic
SSI Eligibility 0.045* 0.044 -0.072*** -0.067**
(0.024) (0.029) (0.026) (0.030)
Mean 0.180 0.183 0.208 0.208
N obs. 2,384 1,676 2,384 1,676
Notes: The coefficient estimates in this table represent the effect of being ineligible for SSI disability payments
on academic outcomes. Coefficient estimates that are significant at 1%, 5%, and 10% level are denoted with
***, **, and * respectively. Standard errors are in parentheses.
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Notes: The figures plot average values for each outcome within the bins to the left and right of
the birth weight thresholds.
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3.6 Discussion
Low birth weight infants have worse health and academic outcomes in both the
short-run and long-run. In this paper, we investigate if SSI disability payments can assist
in mitigating the adverse effects of low birth weight.
In this paper, we implement a regression discontinuity design to estimate the effects
of SSI eligibility for infants on future academic outcomes. Our results show that individuals
eligible for SSI disability are less likely to repeat a grade, but are more likely to have a
registered learning disability in school.
Our findings suggest that SSI disability eligibility can have positive effects on future
academic performance. Given that SSI eligibility also makes it more likely for a child to be
diagnosed with a learning disability, it is plausible that disability payments allow parents to





Appendix A ADHD Medication Effects on Primary and Sec-
ondary Students’ Academic Achievement
Table 6: Effects of ADHD Medication on English, Math, & Science Test Scores
Elementary School Middle School
English Math Science English Math Science
Panel A. Female Combined-ADHD:
Treatment -0.184** -0.218*** -0.159* -0.471*** -0.496*** -0.459***
(0.085) (0.082) (0.082) (0.075) (0.072) (0.080)
Mean 2.737 2.338 2.244 2.371 2.119 2.249
N obs. 10,169 10,233 6,924 8,244 8,243 5,519
R2 0.206 0.212 0.225 0.228 0.214 0.229
Panel B. Male Combined-ADHD:
Treatment 0.010 0.051 0.027 -0.100 -0.094 -0.087
(0.078) (0.077) (0.075) (0.072) (0.072) (0.085)
Mean 2.624 2.404 2.318 2.215 2.077 2.232
N obs. 22,421 22,542 15,067 17,284 17,281 11,594
R2 0.193 0.201 0.215 0.186 0.183 0.193
Panel C. Female PI-ADHD:
Treatment -0.192 -0.016 -0.158 -0.158 0.049 0.266
(0.189) (0.184) (0.178) (0.156) (0.150) (0.162)
Mean 2.710 2.309 2.252 2.371 2.116 2.279
N obs. 3,540 3,551 2,405 3,809 3,807 2,541
R2 0.231 0.215 0.233 0.213 0.207 0.224
Panel D. Male PI-ADHD:
Treatment 0.241 0.346** 0.300** -0.060 0.120 -0.182
(0.149) (0.147) (0.148) (0.148) (0.144) (0.155)
Mean 2.623 2.413 2.350 2.240 2.086 2.273
N obs. 6,125 6,157 4,131 6,195 6,190 4,128
R2 0.191 0.191 0.208 0.196 0.176 0.215
Notes: The coefficient estimates in this table can be interpreted as the effect of ADHD medication within a year
of the individual’s ADHD diagnosis on the individual’s English, math and science test score. All specifications
include school controls, birth year, year of diagnosis, and school year controls. We also control for the individual’s
grade, comorbid psychiatric conditions, if the individual is English proficient, mother’s age and education at
birth, family income, number of children and adults in the household, and number of patients diagnosed by the
individual’s diagnosing provider. Coefficient estimates that are significant at 1%, 5%, and 10% level are denoted
with ***, **, and * respectively. Standard errors are in parentheses. They are clustered by individual’s provider
who diagnosed them with ADHD.
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Table 7: ADHD Treatment Effects on Elementary & Middle School Test Scores: By Gender
Elementary School Middle School
Female Male Female Male
OLS IV OLS IV OLS IV OLS IV
Treatment -0.061*** -0.047 -0.001 0.014 -0.090*** -0.180*** -0.042*** -0.036
(0.011) (0.040) (0.007) (0.037) (0.012) (0.034) (0.009) (0.034)
Race: Black -0.203*** -0.201*** -0.196*** -0.195*** -0.190*** -0.199*** -0.192*** -0.192***
(0.011) (0.011) (0.008) (0.009) (0.012) (0.012) (0.008) (0.008)
Hispanic -0.079 -0.077 -0.071* -0.069 0.082 0.062 -0.060 -0.059
(0.051) (0.051) (0.042) (0.043) (0.077) (0.078) (0.048) (0.048)
Other -0.074*** -0.072*** -0.107*** -0.107*** -0.073*** -0.083*** -0.129*** -0.129***
(0.026) (0.026) (0.015) (0.015) (0.026) (0.027) (0.018) (0.018)
Num children in HH -0.012** -0.011** -0.009*** -0.009*** -0.007 -0.008 -0.007** -0.007**
(0.005) (0.005) (0.003) (0.003) (0.006) (0.006) (0.003) (0.003)
Free lunch -0.024 -0.025 -0.061*** -0.061*** -0.040** -0.037** -0.057*** -0.057***
(0.017) (0.017) (0.013) (0.013) (0.017) (0.017) (0.011) (0.011)
Mother’s Educ: Less than HS -0.074*** -0.073*** -0.051*** -0.051*** -0.122*** -0.119*** -0.080*** -0.080***
(0.026) (0.026) (0.020) (0.019) (0.023) (0.023) (0.021) (0.021)
Some HS -0.067*** -0.067*** -0.040*** -0.041*** -0.052*** -0.050*** -0.036*** -0.036***
(0.012) (0.012) (0.007) (0.007) (0.012) (0.012) (0.009) (0.009)
Some college 0.052*** 0.052*** 0.055*** 0.055*** 0.094*** 0.096*** 0.060*** 0.060***
(0.017) (0.017) (0.012) (0.012) (0.019) (0.019) (0.014) (0.014)
College degree 0.018 0.018 0.086*** 0.087*** 0.077** 0.077** 0.071*** 0.071***
(0.026) (0.025) (0.018) (0.018) (0.031) (0.031) (0.019) (0.019)
Mental condition -0.051*** -0.051*** -0.055*** -0.055*** -0.020* -0.018 -0.044*** -0.044***
(0.011) (0.011) (0.007) (0.007) (0.012) (0.012) (0.008) (0.008)
Mean 0.406 0.403 0.322 0.290
N obs. 14,071 29,185 12,340 23,924
R2 0.148 0.148 0.151 0.151 0.158 0.150 0.136 0.136
Notes: The coefficient estimates in this table can be interpreted as the effect of ADHD medication within a year
of the individual’s ADHD diagnosis on the probability of passing both the English and mathematics examinations.
All specifications include school controls, birth year, year of diagnosis, and school year controls. We also control
for the individual’s grade, comorbid psychiatric conditions, if the individual is English proficient, mother’s age
and education at birth, family income, number of children and adults in the household, and number of patients
diagnosed by the individual’s diagnosing provider. Coefficient estimates that are significant at 1%, 5%, and 10%
level are denoted with ***, **, and * respectively. Standard errors are in parentheses. They are clustered by
individual’s provider who diagnosed them with ADHD.
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Table 8: ADHD Treatment Effects on High School Test Scores: By Gender
Female Male
OLS IV OLS IV
Treatment -0.075*** -0.170*** -0.027 0.002
(0.019) (0.053) (0.016) (0.057)
Race: Black -0.171*** -0.184*** -0.195*** -0.192***
(0.021) (0.023) (0.017) (0.018)
Hispanic -0.044 -0.020 0.007 0.010
(0.102) (0.092) (0.067) (0.067)
Other -0.091* -0.113** -0.151*** -0.149***
(0.048) (0.048) (0.034) (0.033)
Num children in HH -0.010 -0.015 -0.005 -0.005
(0.009) (0.009) (0.007) (0.007)
Free lunch -0.028 -0.019 -0.056** -0.057***
(0.028) (0.028) (0.022) (0.022)
Mental condition -0.108*** -0.110*** -0.076*** -0.074***
(0.021) (0.020) (0.016) (0.016)
Mean 0.560 0.498
N obs. 2,693 4,365
R2 0.195 0.233 0.179 0.178
Notes: The coefficient estimates in this table can be interpreted as the effect of ADHD medication within
a year of the individual’s ADHD diagnosis on the probability of passing both the English and mathematics
examinations. All specifications include school controls, birth year, year of diagnosis, and school year
controls. We also control for the individual’s grade, comorbid psychiatric conditions, if the individual is
English proficient, mother’s age and education at birth, family income, number of children and adults in the
household, and number of patients diagnosed by the individual’s diagnosing provider. Coefficient estimates
that are significant at 1%, 5%, and 10% level are denoted with ***, **, and * respectively. Standard errors
are in parentheses. They are clustered by individual’s provider who diagnosed them with ADHD.
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Table 9: ADHD Treatment Effects on Elementary School Test Scores
Combined Hyper/Inatt Predominantly Inattentive
Female Male Female Male
OLS IV OLS IV OLS IV OLS IV
Treatment -0.059*** -0.046 0.001 -0.024 -0.087*** -0.164 -0.008 0.178**
(0.013) (0.043) (0.009) (0.039) (0.022) (0.108) (0.018) (0.083)
Race: Black -0.186*** -0.185*** -0.193*** -0.195*** -0.219*** -0.228*** -0.182*** -0.181***
(0.014) (0.014) (0.010) (0.011) (0.025) (0.029) (0.017) (0.017)
Hispanic -0.050 -0.047 -0.053 -0.056 -0.067 -0.071 -0.046 -0.046
(0.065) (0.066) (0.050) (0.051) (0.069) (0.069) (0.074) (0.079)
Other -0.101*** -0.100*** -0.096*** -0.097*** 0.039 0.034 -0.068* -0.066*
(0.028) (0.028) (0.017) (0.017) (0.059) (0.061) (0.039) (0.039)
Num children in HH -0.009 -0.009 -0.008** -0.008** -0.032*** -0.033*** -0.011 -0.009
(0.007) (0.007) (0.004) (0.004) (0.010) (0.010) (0.009) (0.009)
Free lunch -0.003 -0.004 -0.049*** -0.049*** -0.017 -0.017 -0.062** -0.055**
(0.020) (0.020) (0.014) (0.014) (0.032) (0.032) (0.026) (0.027)
Mother’s Educ: Less than HS -0.067** -0.067** -0.036 -0.035 -0.095 -0.097 -0.095** -0.091**
(0.028) (0.028) (0.022) (0.022) (0.063) (0.065) (0.042) (0.043)
Some HS -0.056*** -0.056*** -0.034*** -0.034*** -0.092*** -0.092*** -0.036** -0.037**
(0.014) (0.014) (0.009) (0.009) (0.026) (0.026) (0.018) (0.018)
Some college 0.064*** 0.064*** 0.055*** 0.055*** -0.026 -0.022 0.049** 0.047*
(0.020) (0.020) (0.014) (0.014) (0.034) (0.034) (0.025) (0.025)
College degree 0.029 0.029 0.081*** 0.079*** -0.002 -0.001 0.138*** 0.150***
(0.028) (0.028) (0.020) (0.020) (0.056) (0.055) (0.038) (0.038)
Mental condition -0.056*** -0.057*** -0.050*** -0.050*** -0.030 -0.022 -0.069*** -0.068***
(0.012) (0.012) (0.007) (0.007) (0.021) (0.023) (0.016) (0.016)
English proficient 0.089 0.089 0.068 0.069 0.047 0.057 0.075 0.060
(0.065) (0.065) (0.049) (0.049) (0.091) (0.094) (0.087) (0.094)
R2 0.247 0.207 0.377 0.289
Notes: The coefficient estimates in this table can be interpreted as the effect of ADHD medication within a year
of the individual’s ADHD diagnosis on the probability of passing both the English and mathematics examinations.
All specifications include school controls, birth year, year of diagnosis, and school year controls. We also control
for the individual’s grade, comorbid psychiatric conditions, if the individual is English proficient, mother’s age
and education at birth, family income, number of children and adults in the household, and number of patients
diagnosed by the individual’s diagnosing provider. Coefficient estimates that are significant at 1%, 5%, and 10%
level are denoted with ***, **, and * respectively. Standard errors are in parentheses. They are clustered by
individual’s provider who diagnosed them with ADHD.
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Table 10: ADHD Treatment Effects on Middle School Test Scores
Combined Hyper/Inatt Predominantly Inattentive
Female Male Female Male
OLS IV OLS IV OLS IV OLS IV
Treatment -0.104*** -0.202*** -0.039*** -0.060 -0.087*** -0.132 -0.059*** -0.005
(0.015) (0.040) (0.009) (0.037) (0.022) (0.081) (0.021) (0.083)
Race: Black -0.206*** -0.214*** -0.195*** -0.197*** -0.219*** -0.145*** -0.171*** -0.169***
(0.014) (0.015) (0.009) (0.010) (0.025) (0.021) (0.018) (0.018)
Hispanic 0.174** 0.144 -0.050 -0.054 -0.067 0.053 -0.011 -0.008
(0.087) (0.088) (0.065) (0.065) (0.069) (0.135) (0.077) (0.076)
Other -0.093*** -0.104*** -0.126*** -0.127*** 0.039 -0.016 -0.133*** -0.134***
(0.032) (0.033) (0.018) (0.018) (0.059) (0.055) (0.036) (0.036)
Num children in HH -0.008 -0.007 -0.009*** -0.009*** -0.032*** 0.004 0.007 0.008
(0.007) (0.007) (0.004) (0.004) (0.010) (0.010) (0.008) (0.008)
Free Lunch -0.021 -0.016 -0.058*** -0.058*** -0.017 -0.050 -0.037* -0.036
(0.020) (0.021) (0.013) (0.013) (0.032) (0.032) (0.022) (0.022)
Mother’s Educ: Less than HS -0.128*** -0.124*** -0.064** -0.064** -0.095 -0.110** -0.093*** -0.095***
(0.026) (0.026) (0.025) (0.025) (0.063) (0.049) (0.036) (0.035)
Some HS -0.051*** -0.050*** -0.032*** -0.032*** -0.092*** -0.089*** -0.040** -0.041**
(0.014) (0.014) (0.010) (0.010) (0.026) (0.024) (0.019) (0.019)
Some college 0.089*** 0.088*** 0.044** 0.044** -0.026 0.108*** 0.078*** 0.078***
(0.023) (0.024) (0.017) (0.017) (0.034) (0.031) (0.024) (0.024)
College degree 0.072* 0.072* 0.056** 0.056** -0.002 0.072 0.091** 0.094**
(0.037) (0.037) (0.022) (0.022) (0.056) (0.055) (0.040) (0.041)
Mental condition -0.022* -0.020 -0.049*** -0.049*** -0.030 0.005 -0.040*** -0.038***
(0.012) (0.012) (0.009) (0.009) (0.021) (0.021) (0.013) (0.014)
English proficient 0.450*** 0.456*** 0.060 0.059 0.047 0.231 0.080 0.073
(0.084) (0.086) (0.069) (0.069) (0.091) (0.146) (0.093) (0.095)
R2 0.230 0.181 0.377 0.211
Notes: The coefficient estimates in this table can be interpreted as the effect of ADHD medication within a year
of the individual’s ADHD diagnosis on the probability of passing both the English and mathematics examinations.
All specifications include school controls, birth year, year of diagnosis, and school year controls. We also control
for the individual’s grade, comorbid psychiatric conditions, if the individual is English proficient, mother’s age
and education at birth, family income, number of children and adults in the household, and number of patients
diagnosed by the individual’s diagnosing provider. Coefficient estimates that are significant at 1%, 5%, and 10%
level are denoted with ***, **, and * respectively. Standard errors are in parentheses. They are clustered by
individual’s provider who diagnosed them with ADHD.
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Table 11: ADHD Treatment Effects on High School Test Scores
Combined Hyper/Inatt Predominantly Inattentive
Female Male Female Male
OLS IV OLS IV OLS IV OLS IV
Treatment -0.070*** -0.190*** -0.114*** -0.066 -0.037* 0.019 -0.006 -0.045
(0.022) (0.065) (0.037) (0.116) (0.019) (0.057) (0.031) (0.132)
Race: Black -0.164*** -0.175*** -0.162*** -0.153*** -0.190*** -0.187*** -0.214*** -0.219***
(0.025) (0.025) (0.038) (0.042) (0.022) (0.022) (0.032) (0.036)
Hispanic -0.021 -0.010 0.456*** 0.459*** 0.002 0.004 0.043 0.035
(0.104) (0.107) (0.149) (0.145) (0.071) (0.071) (0.100) (0.105)
Other -0.116* -0.120** -0.071 -0.079 -0.163*** -0.158*** -0.201*** -0.198***
(0.061) (0.061) (0.082) (0.081) (0.037) (0.038) (0.072) (0.074)
Num children in HH -0.009 -0.010 -0.022 -0.021 -0.012 -0.012 0.010 0.010
(0.012) (0.012) (0.018) (0.018) (0.009) (0.008) (0.015) (0.015)
Free lunch -0.025 -0.021 0.010 0.006 -0.047* -0.049* -0.089** -0.089**
(0.034) (0.035) (0.043) (0.043) (0.026) (0.026) (0.041) (0.041)
Mental condition -0.096*** -0.094*** -0.093** -0.096*** -0.081*** -0.078*** -0.070*** -0.073***
(0.026) (0.026) (0.036) (0.037) (0.018) (0.018) (0.027) (0.028)
englishprof 0.031 0.076 0.726*** 0.716*** 0.092 0.085 0.172 0.178
(0.131) (0.136) (0.208) (0.201) (0.116) (0.116) (0.136) (0.140)
R2 0.312 0.383 0.265 0.288
Notes: The coefficient estimates in this table can be interpreted as the effect of ADHD medication within a year
of the individual’s ADHD diagnosis on the probability of passing both the English and mathematics examinations.
All specifications include school controls, birth year, year of diagnosis, and school year controls. We also control
for the individual’s grade, comorbid psychiatric conditions, if the individual is English proficient, mother’s age
and education at birth, family income, number of children and adults in the household, and number of patients
diagnosed by the individual’s diagnosing provider. Coefficient estimates that are significant at 1%, 5%, and 10%
level are denoted with ***, **, and * respectively. Standard errors are in parentheses. They are clustered by
individual’s provider who diagnosed them with ADHD.
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Table 12: IV Probit: Fraction of years treated with medication
Elementary School Middle School High School
Panel A. Female Combined-ADHD:
Treatment -0.073 -0.259*** -0.330***
(0.050) (0.038) (0.102)
Mean 0.408 0.320 0.548
N obs. 10,167 8,240 1,685
Panel B. Male Combined-ADHD:
Treatment -0.035 -0.088** 0.162
(0.047) (0.045) (0.322)
Mean 0.402 0.291 0.489
N obs. 22,398 17,267 2,939
Panel C. Female PI-ADHD:
Treatment -0.126 -0.143 -0.102
(0.119) (0.111) (0.228)
Mean 0.393 0.324 0.582
N obs. 3,537 3,805 962
Panel D. Male PI-ADHD:
Treatment 0.327*** 0.079 -0.251
(0.093) (0.113) (0.245)
Mean 0.411 0.292 0.517
N obs. 6,122 6,187 1,351
Notes: Treatment is defined as the fraction of Medicaid eligible years the individual takes ADHD medication
after their ADHD diagnosis. The outcome variable is defined as the probability of passing both the English and
mathematics examinations. All specifications include school controls, birth year, year of diagnosis, and school
year controls. We also control for the individual’s grade, comorbid psychiatric conditions, if the individual is
English proficient, mother’s age and education at birth, family income, number of children and adults in the
household, and number of patients diagnosed by the individual’s diagnosing provider. Coefficient estimates that
are significant at 1%, 5%, and 10% level are denoted with ***, **, and * respectively. Standard errors are in
parentheses. They are clustered by individual’s provider who diagnosed them with ADHD.
102
Table 13: Summary Statistics: Individual and Family Characteristics; Undiagnosed Chil-
dren
N obs. Mean Median SD Min Max
Individual characteristics
Age 1st in sample 134,075 7.83 8.00 5.02 1 19
Male 134,075 0.45 0 1
Race: White 134,075 0.35 0 1
Black 134,075 0.55 0 1
Hispanic 134,075 0.05 0 1
Family & home environment
Monthly family net income 134,075 717.06 573.5 660.72 0 6,356
Number of adults 134,075 1.25 1.14 0.58 0 3
Number of children 134,075 2.07 2.00 1.06 0 6
Ever in foster care 134,075 0.04 0 1
Ever had disability 134,075 0.05 0 1
Mother’s characteristics
Age when gave birth 73,923 23.60 22.00 5.62 11 48
Educ: Less than HS 73,923 0.06 0 1
Some HS 73,923 0.33 0 1
HS diploma 73,923 0.42 0 1
Some college 73,923 0.14 0 1
College degree or higher 73,923 0.05 0 1
Notes: The sample includes a random group of SC Medicaid enrollees, who were eligible for Medicaid for at least
one year at any age between 3 and 18 years old in 2003-2013 and who did not have an ADHD-related medical
history during this time period. Family characteristics are reported on average per patient/eligibility year. Foster
care and disability rates are calculated based on the Medicaid enrollment categories. Mother characteristics are
reported based on in-state birth certificate information matched to Medicaid records. They are available only
for a subsample of the 73,923 patients. Mother’s age and educational attainment are recorded at the time of the
child’s birth. “HS” stands for high school education level.
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Table 14: Summary Statistics: Provider/Patients
Providers Patients per provider
Diagnosis year Number/year Mean Std
2003 447 9.667 15.999
2004 560 12.320 24.027
2005 496 11.048 19.484
2006 454 9.991 17.254
2007 476 9.845 17.474
2008 572 9.210 16.618
2009 672 8.330 14.724
2010 787 8.625 12.987
2011 835 8.503 13.581
2012 874 8.572 13.042
Total number of individual doctors 1,953
Total number of doctor/years 6,371
Table 15: Evidence of Treatment Shopping




Race: Black 0.0001 0.003
Hispanic 0.010 0.016
Other -0.005 0.007
Mother’s Educ: Less than HS -0.009 0.010
Some HS 0.0004 0.007
HS degree -0.009 0.007
Some college -0.0114 0.008
Family income 0.0001 0.002
Num children -0.005*** 0.001
Num adults -0.003 0.003
Obs 41,721
R2 0.024
Notes: The dependent variable is equal to 1 if an individual switches to a subsequent doctor,
0 otherwise. The variable ”extreme” is equal to 1 if the individual’s first provider diagnosis all
of his patients or none of his patients, 0 otherwise. Coefficient estimates that are significant
at 1%, 5%, and 10% level are denoted with ***, **, and * respectively.
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Table 16: Summary statistics: Switchers
DocPTP1 > DocPTP2 DocPTP1 < DocPTP2
Variable Mean Std Dev N Mean Std Dev N
Mother’s Educ: Less than HS 0.042 0.200 1634 0.047 0.211 2485
Some HS 0.390 0.488 1634 0.395 0.489 2485
HS degree 0.376 0.484 1634 0.384 0.487 2485
Some college 0.125 0.331 1634 0.125 0.331 2485
College degree 0.065 0.246 1634 0.048 0.214 2485
Mother’s age 23.697 5.612 1645 23.357 5.410 2503
Family income 0.518 0.756 2261 0.541 0.778 3290
Num children 1.971 1.088 2261 2.028 1.086 3290
Num adults 0.912 0.742 2261 0.929 0.753 3290
Notes: The summary statistics are reported for individuals who switch providers. DocPTP1 represents the
individuals’ first provider propensity to prescribe, and DocPTP2 represents the individuals’ subsequent provider
propensity to prescribe.
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Appendix B Sex, Drugs, and ADHD: The Effects of ADHD
Pharmacological Treatment on Teens’ Risky Be-
haviors
Table 17: Summary Statistics: Individual and Family Characteristics; Undiagnosed Chil-
dren
N obs. Mean Median SD Min Max
Individual characteristics
Age 1st in sample 134,075 7.83 8.00 5.02 1 19
Male 134,075 0.45 0 1
Race: White 134,075 0.35 0 1
Black 134,075 0.55 0 1
Hispanic 134,075 0.05 0 1
Family & home environment
Monthly family net income 134,075 717.06 573.5 660.72 0 6,356
Number of adults 134,075 1.25 1.14 0.58 0 3
Number of children 134,075 2.07 2.00 1.06 0 6
Ever in foster care 134,075 0.04 0 1
Ever had disability 134,075 0.05 0 1
Mother’s characteristics
Age when gave birth 73,923 23.60 22.00 5.62 11 48
Educ: Less than HS 73,923 0.06 0 1
Some HS 73,923 0.33 0 1
HS diploma 73,923 0.42 0 1
Some college 73,923 0.14 0 1
College degree or higher 73,923 0.05 0 1
Notes: The sample includes a random group of SC Medicaid enrollees, who were eligible for Medicaid for at least
one year at any age between 3 and 18 years old in 2003-2013 and who did not have an ADHD-related medical
history during this time period. Family characteristics are reported on average per patient/eligibility year. Foster
care and disability rates are calculated based on the Medicaid enrollment categories. Mother characteristics are
reported based on in-state birth certificate information matched to Medicaid records. They are available only
for a subsample of the 73,923 patients. Mother’s age and educational attainment are recorded at the time of the
child’s birth. “HS” stands for high school education level.
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Table 18: Summary Statistics: Negative Health Outcomes; Undiagnosed Children
N obs. Mean Median SD Min Max
Years in sample 134,075 6.72 6.00 3.08 1 11
Outcome: Risky sexual behavior
1. Teen Pregnancy
Age at 1st pregnancy 19,750 17.47 18.00 1.42 11 19
Race: White 19,750 0.42 0 1
Black 19,750 0.53 0 1
2. STD
Age at 1st STD 14,687 16.02 17.00 2.46 11 19
Age at 1st STD (incl. screening) 26,334 16.33 17.00 2.21 11 19
Male 14,687 0.23 0 1
Race: White 14,687 0.38 0 1
Black 14,687 0.56 0 1
Annual cost of STD 14,687 397.61 143.49 1283.26 1 90,461
Annual cost of STD+test 26,334 341.62 169.70 932.95 1 90,461
Outcome: Substance Abuse
Age at 1st substance abuse 15,073 16.53 17.00 1.92 11 19
Male 15,073 0.47 0 1
Race: White 15,073 0.50 0 1
Black 15,073 0.45 0 1
Annual cost of substance abuse 15,073 1501.46 439.32 3736.11 1 109,293
Outcome: Injuries
Ever injured 134,075 0.86 0 1
Age at injury 115,526 10.92 11.00 4.41 3 19
Male 115,526 0.48 0 1
Race: White 115,526 0.39 0 1
Black 115,526 0.51 0 1
N of injury claims 134,075 0.36 0.25 0.42 0 11
Annual cost of injuries 115,526 702.09 213.11 3463.53 2 394,516
Notes: The sample includes a random group of SC Medicaid enrollees, who were eligible for Medicaid for at
least one year at any age between 3 and 18 years old in 2003-2013 and who did not have an ADHD-related
medical history during this time period. Annual costs of negative health outcomes are given in 2013 dollars
per patient/year conditional on the occurrence of a negative health outcome. They are based on the Medicaid
reimbursement. The out-of-pocket patient costs are nearly zero for our population of interest.
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Table 19: Evidence of Treatment Shopping: Predictors of provider switching
Regressors Coeff SE
“Extreme” provider 0.020a 0.004
Race: Black -0.001 0.004
Hispanic -0.009 0.012
Other -0.010 0.007
Mother’s Educ: Some HS 0.010 0.008
HS degree -0.001 0.008
Some college -0.001 0.009
College degree or higher 0.008 0.010
Family net income 0.0003 0.002
Number of children -0.006a 0.002
Number of adults -0.006b 0.003
N obs. 42,693
R2 0.016
Notes: The dependent variable is equal to 1 if an individual switches providers;
0 otherwise. The variable ”extreme” provider is equal to 1 if the individual’s first
provider diagnoses all of his patients or none of his patients; 0 otherwise. Coefficient
estimates that are significant at 1%, 5%, and 10% level are denoted with a, b, and
c respectively.
Table 20: Summary statistics: Switchers
PP1 > PP2 PP1 < PP2
Variable Mean SD N obs. Mean SD N obs.
Mother’s Educ: Less than HS 0.042 0.200 1,635 0.047 0.211 2,486
Some HS 0.391 0.488 1,635 0.395 0.489 2,486
HS degree 0.376 0.484 1,635 0.385 0.487 2,486
Some college 0.125 0.331 1,635 0.125 0.331 2,486
College degree 0.065 0.246 1,635 0.048 0.214 2,486
Mother’s age 23.691 5.614 1,646 23.356 5.409 2,504
Family net income 0.518 0.756 2,262 0.541 0.778 3,291
Number of children 1.971 1.088 2,262 2.028 1.086 3,291
Number of adults 0.912 0.742 2,262 0.929 0.753 3,291
Notes: This table reports summary statistics for individuals who switch providers. PP1 stands for the first



















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Appendix C Social Security Supplemental Security Income
(SSI) Disability Benefits on Future Educational
Achievement
Table 23: Robustness: SSI Disability Eligibility on Outcomes Excluding 1500g Threshold
Grade Repetition Learning Disability
200g window 150g window 200g window 150g window
Flexible Linear
SSI Eligibility 0.065** 0.049 -0.084** -0.079*
(0.033) (0.039) (0.035) (0.041)
Flexible Quadratic
SSI Eligibility 0.043* 0.037 -0.077*** -0.074**
(0.025) (0.029) (0.026) (0.030)
Mean 0.179 0.182 0.208 0.207
N obs. 2257 1583 2257 1583
Notes: The coefficient estimates in this table represent the effect of being ineligible for SSI disability payments
on academic outcomes. Coefficient estimates that are significant at 1%, 5%, and 10% level are denoted with
***, **, and * respectively. Standard errors are in parentheses.
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